required	O
for	O
pervanadate-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
but	O
not	O
for	O
Tyr42	O
phosphorylation	O
.	O
These	O
results	O
show	O
that	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
ZAP-70	B-protein
are	O
key	O
components	O
of	O
the	O
signaling	O
pathway	O
that	O
leads	O
to	O
phosphotyrosine-dependent	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
T	O
cells	O
and	O
confirm	O
that	O
tyrosine	B-protein
kinases	I-protein
must	O
control	O
at	O
least	O
two	O
different	O
steps	O
to	O
induce	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
Finally	O
,	O
we	O
show	O
that	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
,	O
which	O
stimulates	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
ZAP-70	B-protein
in	O
T	O
cells	O
,	O
is	O
an	O
activator	O
of	O
NF-kappa	B-protein
B	I-protein
through	O
tyrosine	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O
Specific	O
missense	O
mutations	O
in	O
NEMO	O
result	O
in	O
hyper-IgM	O
syndrome	O
with	O
hypohydrotic	O
ectodermal	O
dysplasia	O
.	O
The	O
gene	O
that	O
encodes	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
essential	O
modulator	O
(	O
or	O
NEMO	O
,	O
also	O
known	O
as	O
IKKgamma	O
)	O
is	O
required	O
for	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappaB	I-protein
.	O
We	O
describe	O
mutations	O
in	O
the	O
putative	B-protein
zinc-finger	I-protein
domain	I-protein
of	O
NEMO	B-protein
that	O
result	O
in	O
an	O
X-linked	O
primary	O
immunodeficiency	O
characterized	O
by	O
hyper-IgM	O
syndrome	O
and	O
hypohydrotic	O
ectodermal	O
dysplasia	O
(	O
XHM-ED	O
)	O
.	O
These	O
mutations	O
prevent	O
CD40	B-protein
ligand	I-protein
(	O
CD40L	B-protein
)	O
-mediated	O
degradation	O
of	O
inhibitor	O
of	O
NF-kappaB	B-protein
alpha	I-protein
(	O
IkappaB-alpha	B-protein
)	O
and	O
account	O
for	O
the	O
following	O
observations	O
:	O
B	O
cells	O
from	O
XHM-ED	O
patients	O
are	O
unable	O
to	O
undergo	O
immunoglobulin	O
class-switch	O
recombination	O
and	O
antigen-presenting	O
cells	O
(	O
APCs	O
)	O
are	O
unable	O
to	O
synthesize	O
the	O
NF-kappaB-regulated	B-protein
cytokines	I-protein
interleukin	B-protein
12	I-protein
(	O
IL-12	B-protein
)	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
when	O
stimulated	O
with	O
CD40L	B-protein
.	O
Nevertheless	O
,	O
innate	O
immunity	O
is	O
preserved	O
in	O
XHM-ED	O
patients	O
because	O
APCs	O
retain	O
the	O
capacity	O
to	O
respond	O
to	O
stimulation	O
by	O
lipopolysaccharide	O
or	O
Staphylococcus	B-protein
aureus	I-protein
Cowan	I-protein
's	I-protein
antigen	I-protein
(	O
SAC	B-protein
)	O
.	O
Overall	O
,	O
the	O
phenotype	O
observed	O
in	O
XHM-ED	O
patients	O
shows	O
that	O
the	O
putative	B-protein
zinc-finger	I-protein
domain	I-protein
of	O
NEMO	B-protein
has	O
a	O
regulatory	O
function	O
and	O
demonstrates	O
the	O
definite	O
requirement	O
of	O
CD40	B-protein
-mediated	O
NF-kappaB	O
activation	O
for	O
B	O
cell	O
immunoglobulin	O
class-switching	O
.	O
Granulocytic	O
differentiation	O
of	O
human	O
NB4	O
promyelocytic	O
leukemia	O
cells	O
induced	O
by	O
all-trans	O
retinoic	O
acid	O
metabolites	O
.	O
The	O
metabolism	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
has	O
been	O
reported	O
to	O
be	O
partly	O
responsible	O
for	O
the	O
in	O
vivo	O
resistance	O
to	O
ATRA	O
seen	O
in	O
the	O
treatment	O
of	O
human	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O
However	O
,	O
ATRA	O
metabolism	O
appears	O
to	O
be	O
involved	O
in	O
the	O
growth	O
inhibition	O
of	O
several	O
cancer	O
cell	O
lines	O
in	O
vitro	O
.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
in	O
vitro	O
activity	O
of	O
the	O
principal	O
metabolites	O
of	O
ATRA	O
[	O
4-hydroxy-retinoic	O
acid	O
(	O
4-OH-RA	O
)	O
,	O
18-hydroxy-retinoic	O
acid	O
(	O
18-OH-RA	O
)	O
,	O
4-oxo-retinoic	O
acid	O
(	O
4-oxo-RA	O
)	O
,	O
and	O
5	O
,	O
6-epoxy-retinoic	O
acid	O
(	O
5	O
,	O
6-epoxy-RA	O
)	O
]	O
in	O
NB4	O
,	O
a	O
human	O
promyelocytic	O
leukemia	O
cell	O
line	O
that	O
exhibits	O
the	O
APL	O
diagnostic	O
t	O
(	O
15	O
;	O
17	O
)	O
chromosomal	O
translocation	O
and	O
expresses	O
the	O
PML-RAR	B-protein
alpha	I-protein
fusion	I-protein
protein	I-protein
.	O
We	O
established	O
that	O
the	O
four	O
ATRA	O
metabolites	O
were	O
indeed	O
formed	O
by	O
the	O
NB4	O
cells	O
in	O
vitro	O
.	O
NB4	O
cell	O
growth	O
was	O
inhibited	O
(	O
69-78	O
%	O
at	O
120	O
h	O
)	O
and	O
cell	O
cycle	O
progression	O
in	O
the	O
G1	O
phase	O
(	O
82-85	O
%	O
at	O
120	O
h	O
)	O
was	O
blocked	O
by	O
ATRA	O
and	O
all	O
of	O
the	O
metabolites	O
at	O
1	O
microM	O
concentration	O
.	O
ATRA	O
and	O
its	O
metabolites	O
could	O
induce	O
NB4	O
cells	O
differentiation	O
with	O
similar	O
activity	O
,	O
as	O
evaluated	O
by	O
cell	O
morphology	O
,	O
by	O
the	O
nitroblue	O
tetrazolium	O
reduction	O
test	O
(	O
82-88	O
%	O
at	O
120	O
h	O
)	O
or	O
by	O
the	O
expression	O
of	O
the	O
maturation	B-protein
specific	I-protein
cell	I-protein
surface	I-protein
marker	I-protein
CD11c	I-protein
.	O
In	O
addition	O
,	O
nuclear	O
body	O
reorganization	O
to	O
macropunctated	O
structures	O
,	O
as	O
well	O
as	O
the	O
degradation	O
of	O
PML-RAR	B-protein
alpha	I-protein
,	O
was	O
found	O
to	O
be	O
similar	O
for	O
ATRA	O
and	O
all	O
of	O
its	O
metabolites	O
.	O
Comparison	O
of	O
the	O
relative	O
potency	O
of	O
the	O
retinoids	O
using	O
the	O
nitroblue	O
tetrazolium	O
reduction	O
test	O
showed	O
effective	O
concentrations	O
required	O
to	O
differentiate	O
50	O
%	O
of	O
cells	O
in	O
72	O
h	O
as	O
follows	O
:	O
ATRA	O
,	O
15.8	O
+/-	O
1.7	O
nM	O
;	O
4-oxo-RA	O
,	O
38.3	O
+/-	O
1.3	O
nM	O
;	O
18-OH-RA	O
,	O
55.5	O
+/-	O
1.8	O
nM	O
;	O
4-OH-RA	O
,	O
79.8	O
+/-	O
1.8	O
nM	O
;	O
and	O
5	O
,	O
6-epoxy-RA	O
,	O
99.5	O
+/-	O
1.5	O
nM	O
.	O
The	O
ATRA	O
metabolites	O
were	O
found	O
to	O
exert	O
their	O
differentiation	O
effects	O
via	O
the	O
RAR	B-protein
alpha	I-protein
nuclear	I-protein
receptors	I-protein
,	O
because	O
the	O
RAR	O
alpha-specific	O
antagonist	O
BMS614	O
blocked	O
metabolite-induced	O
CD11c	O
expression	O
in	O
NB4	O
cells	O
.	O
These	O
data	O
demonstrate	O
that	O
the	O
principal	O
ATRA	O
Phase	O
1	O
metabolites	O
can	O
elicit	O
leukemia	O
cell	O
growth	O
inhibition	O
and	O
differentiation	O
in	O
vitro	O
through	O
the	O
RAR	O
alpha	O
signaling	O
pathway	O
,	O
and	O
they	O
suggest	O
that	O
these	O
metabolites	O
may	O
play	O
a	O
role	O
in	O
ATRA	O
antileukemic	O
activity	O
in	O
vivo	O
.	O
Expression	O
of	O
oestrogen	B-protein
and	I-protein
progesterone	I-protein
receptors	I-protein
by	O
mast	O
cells	O
alone	O
,	O
but	O
not	O
lymphocytes	O
,	O
macrophages	O
or	O
other	O
immune	O
cells	O
in	O
human	O
upper	O
airways	O
.	O
BACKGROUND	O
:	O
Nasal	O
polyposis	O
often	O
coexists	O
with	O
asthma	O
in	O
airway	O
inflammatory	O
conditions	O
characterised	O
by	O
the	O
infiltration	O
of	O
a	O
range	O
of	O
immune	O
cells	O
.	O
A	O
potentially	O
important	O
role	O
for	O
ovarian	O
hormones	O
has	O
been	O
implicated	O
in	O
airway	O
inflammation	O
but	O
the	O
cellular	O
target	O
for	O
such	O
action	O
is	O
not	O
known	O
.	O
METHODS	O
:	O
Expression	O
of	O
oestrogen	B-protein
receptors	I-protein
(	O
ER	B-protein
)	O
and	O
progesterone	B-protein
receptors	I-protein
(	O
PR	B-protein
)	O
was	O
examined	O
using	O
immunohistochemistry	O
in	O
formalin	O
fixed	O
nasal	O
polyp	O
tissues	O
from	O
47	O
subjects	O
.	O
The	O
cells	O
positive	O
for	O
ER	B-protein
or	O
PR	B-protein
were	O
confirmed	O
by	O
spatial	O
location	O
,	O
dual	O
immunolabelling	O
,	O
and	O
histochemical	O
staining	O
.	O
RESULTS	O
:	O
Consistent	O
with	O
the	O
known	O
features	O
of	O
nasal	O
polyps	O
,	O
CD4+	O
(	O
T	O
helper/inducer	O
)	O
,	O
CD8+	O
(	O
cytotoxic/suppressor	O
)	O
,	O
CD68+	O
(	O
macrophages	O
)	O
,	O
mast	O
cells	O
,	O
eosinophils	O
and	O
neutrophils	O
were	O
all	O
clearly	O
detected	O
by	O
their	O
relevant	O
monoclonal	B-protein
antibodies	I-protein
or	O
appropriate	O
histochemical	O
staining	O
,	O
but	O
only	O
mast	O
cells	O
tested	O
positive	O
for	O
ER	B-protein
/PR	O
labelling	O
with	O
their	O
polyclonal	B-protein
and	I-protein
monoclonal	I-protein
antibodies	I-protein
.	O
The	O
frequencies	O
for	O
expression	O
were	O
61.7	O
%	O
for	O
ER	O
positive	O
and	O
59.6	O
%	O
for	O
PR	O
positive	O
cells	O
.	O
The	O
expression	O
of	O
ER	B-protein
/	O
PR	B-protein
was	O
independent	O
of	O
patient	O
sex	O
and	O
age	O
but	O
was	O
highly	O
correlated	O
with	O
the	O
numbers	O
of	O
mast	O
cells	O
(	O
r	O
=	O
0.973	O
,	O
p	O
<	O
0.001	O
for	O
ER	B-protein
;	O
r	O
=	O
0.955	O
,	O
p	O
<	O
0.001	O
for	O
PR	B-protein
)	O
.	O
Fewer	O
than	O
5	O
%	O
of	O
mast	O
cells	O
were	O
found	O
to	O
be	O
negative	O
for	O
ER	B-protein
/	O
PR	B-protein
expression	O
.	O
CONCLUSIONS	O
:	O
Mast	O
cells	O
alone	O
,	O
but	O
not	O
lymphocytes	O
,	O
macrophages	O
,	O
or	O
other	O
immune	O
cells	O
,	O
express	O
ER	B-protein
/	O
PR	B-protein
in	O
human	O
upper	O
airways	O
.	O
Numerous	O
ER/PR	O
positive	O
mast	O
cells	O
exist	O
in	O
nasal	O
polyps	O
,	O
indicating	O
that	O
this	O
may	O
be	O
a	O
major	O
route	O
for	O
the	O
involvement	O
of	O
sex	O
hormones	O
in	O
airway	O
inflammation	O
when	O
exposed	O
to	O
the	O
higher	O
and	O
varying	O
concentration	O
of	O
oestrogen	O
and	O
progesterone	O
characteristic	O
of	O
females	O
.	O
NF	O
kappa	O
b	O
signaling	O
in	O
posthypoxic	O
endothelial	O
cells	O
:	O
relevance	O
to	O
E-selectin	O
expression	O
and	O
neutrophil	O
adhesion	O
.	O
Our	O
previous	O
studies	O
have	O
implicated	O
the	O
nuclear	O
transcription	O
factor	O
kappa	O
B	O
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
in	O
the	O
regulation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
in	O
endothelial	O
cells	O
exposed	O
to	O
anoxia-reoxygenation	O
(	O
A/R	O
)	O
or	O
a	O
redox	O
imbalance	O
.	O
The	O
objectives	O
of	O
this	O
study	O
were	O
(	O
1	O
)	O
to	O
define	O
the	O
kinetics	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
by	O
examining	O
I	O
kappa	O
B	O
alpha	O
degradation	O
and	O
the	O
nuclear	O
translocation	O
of	O
p65	B-protein
in	O
response	O
to	O
A/R	O
or	O
redox	O
imbalance	O
(	O
induced	O
by	O
treatment	O
of	O
cells	O
with	O
diamide	O
and	O
buthionine	O
sulfoximine	O
)	O
and	O
(	O
2	O
)	O
to	O
determine	O
whether	O
the	O
signal	O
for	O
I	O
kappa	O
B	O
alpha	O
degradation	O
,	O
nuclear	O
translocation	O
of	O
p65	B-protein
,	O
and	O
E-selectin	B-protein
-mediated	O
neutrophil	O
adhesion	O
is	O
related	O
to	O
the	O
activity	O
of	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
(	O
PTK	B-protein
)	O
,	O
protein	B-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
PTPase	B-protein
)	O
and/or	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O
The	O
results	O
demonstrate	O
that	O
both	O
A/R	O
and	O
redox	O
imbalance	O
led	O
to	O
I	O
kappa	O
B	O
alpha	O
degradation	O
within	O
30	O
min	O
and	O
the	O
concomitant	O
appearance	O
of	O
p65	B-protein
in	O
the	O
nucleus	O
,	O
consistent	O
with	O
rapid	O
cytosolic	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
and	O
subsequent	O
nuclear	O
translocation	O
of	O
the	O
activated	B-protein
p65	I-protein
subunit	I-protein
.	O
Inhibition	O
of	O
PKC	B-protein
blocked	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
and	O
p65	B-protein
translocation	O
in	O
A/R-challenged	O
,	O
but	O
not	O
redox-altered	O
,	O
endothelial	O
cells	O
.	O
However	O
,	O
both	O
A/R-	O
and	O
redox-induced	O
NF	O
kappa	O
B	O
activation	O
was	O
blocked	O
by	O
inhibition	O
of	O
PTK	B-protein
.	O
Similarly	O
,	O
A/R-induced	O
E-selectin	O
expression	O
and	O
neutrophil-endothelial	O
cell	O
adhesion	O
were	O
blocked	O
by	O
inhibition	O
of	O
PKC	B-protein
or	O
PTK	B-protein
,	O
while	O
only	O
PTK	B-protein
inhibited	O
the	O
redox-induced	O
adhesion	O
response	O
.	O
Pretreatment	O
of	O
cells	O
with	O
N-acetyl	O
cysteine	O
effectively	O
blocked	O
A/R-	O
or	O
redox-induced	O
I	O
kappa	O
B	O
degradation	O
and	O
significantly	O
attenuated	O
the	O
respective	O
neutrophil	O
adhesion	O
responses	O
.	O
Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A/R-induced	O
E-selectin	O
expression	O
and	O
neutrophil-endothelial	O
cell	O
adhesion	O
are	O
mediated	O
by	O
both	O
PKC	B-protein
and	O
PTK	B-protein
,	O
which	O
signal	O
rapid	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O
This	O
A/R-induced	O
NF	B-protein
kappa	I-protein
B	I-protein
signaling	O
response	O
appears	O
to	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
intracellular	O
redox	O
imbalance	O
.	O
Copyright	O
2001	O
S.	O
Karger	O
AG	O
,	O
Basel	O
Induction	O
of	O
apoptosis	O
in	O
human	O
lymphocytes	O
by	O
the	O
herbicide	O
2	O
,	O
4-dichlorophenoxyacetic	O
acid	O
.	O
Dimethylammonium	O
salt	O
of	O
2	O
,	O
4-dichlorophenoxyacetic	O
acid	O
(	O
DMA-2	O
,	O
4-D	O
)	O
is	O
a	O
widely	O
used	O
herbicide	O
that	O
is	O
considered	O
moderately	O
toxic	O
.	O
In	O
the	O
present	O
study	O
we	O
found	O
that	O
DMA-2	O
,	O
4-D	O
is	O
able	O
to	O
cause	O
apoptosis	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
healthy	O
individuals	O
and	O
Jurkat	O
T	O
cells	O
.	O
Apoptosis	O
induced	O
by	O
DMA-2	O
,	O
4-D	O
was	O
dose	O
and	O
time	O
dependent	O
,	O
independent	O
of	O
Fas	B-protein
,	O
TNF	B-protein
receptor	I-protein
1	I-protein
or	O
the	O
aromatic	B-protein
hydrocarbon	I-protein
receptor	I-protein
,	O
and	O
involved	O
disruption	O
of	O
the	O
mitochondrial	O
transmembrane	O
potential	O
and	O
activation	O
of	O
caspase-9	B-protein
.	O
ZVAD-FMK	O
,	O
a	O
broad-spectrum	O
inhibitor	O
of	O
caspases	B-protein
,	O
blocked	O
DMA-2	O
,	O
4-D-induced	O
apoptosis	O
completely	O
.	O
While	O
an	O
inhibitor	O
of	O
caspase-9	B-protein
,	O
as	O
well	O
as	O
caspase-9	B-protein
and	O
caspase-3	O
inhibitors	O
in	O
combination	O
,	O
strongly	O
blocked	O
DMA-2	O
,	O
4-D-induced	O
apoptosis	O
,	O
an	O
inhibitor	O
of	O
caspase-3	B-protein
had	O
a	O
moderate	O
inhibitory	O
effect	O
.	O
Unlike	O
Fas	B-protein
-mediated	O
apoptosis	O
,	O
the	O
initiator	B-protein
caspase	I-protein
,	O
caspase-8	B-protein
,	O
was	O
not	O
involved	O
in	O
DMA-2	O
,	O
4-D-induced	O
apoptosis	O
.	O
Transfection	O
of	O
Jurkat	O
cells	O
with	O
Bcl-2	B-protein
prevented	O
DMA-2	O
,	O
4-D-induced	O
disruption	O
of	O
the	O
mitochondrial	O
transmembrane	O
potential	O
and	O
led	O
to	O
a	O
complete	O
blockage	O
of	O
apoptosis	O
.	O
Our	O
data	O
indicate	O
that	O
DMA-2	O
,	O
4-D	O
kills	O
human	O
lymphocytes	O
by	O
initiating	O
apoptosis	O
via	O
a	O
direct	O
effect	O
on	O
mitochondria	O
.	O
The	O
activation	O
of	O
caspases	B-protein
occurs	O
downstream	O
of	O
mitochondrial	O
damage	O
,	O
and	O
the	O
dysfunction	O
of	O
mitochondria	O
appears	O
to	O
be	O
sufficient	O
for	O
triggering	O
all	O
downstream	O
events	O
leading	O
to	O
apoptosis	O
.	O
Inhibition	O
of	O
Th1	O
differentiation	O
by	O
IL-6	B-protein
is	O
mediated	O
by	O
SOCS1	B-protein
.	O
Interleukin	B-protein
6	I-protein
(	O
IL-6	B-protein
)	O
is	O
a	O
cytokine	B-protein
produced	O
by	O
immune	O
and	O
nonimmune	O
cells	O
and	O
exhibits	O
functional	O
pleiotropy	O
and	O
redundancy	O
.	O
IL-6	B-protein
plays	O
an	O
important	O
role	O
in	O
the	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O
Here	O
,	O
we	O
describe	O
a	O
novel	O
function	O
of	O
IL-6	B-protein
:	O
the	O
negative	O
regulation	O
of	O
CD4	B-protein
+	O
Th1	O
cell	O
differentiation	O
.	O
While	O
IL-6	B-protein
-directed	O
CD4	B-protein
+	O
Th2	O
differentiation	O
is	O
mediated	O
by	O
IL-4	B-protein
,	O
inhibition	O
of	O
Th1	O
differentiation	O
by	O
IL-6	B-protein
is	O
independent	O
of	O
IL-4	B-protein
.	O
IL-6	B-protein
upregulates	O
suppressor	B-protein
of	I-protein
cytokine	I-protein
signaling	I-protein
1	I-protein
(	O
SOCS1	B-protein
)	O
expression	O
in	O
activated	O
CD4+	O
T	O
cells	O
,	O
thereby	O
interfering	O
with	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
1	I-protein
(	O
STAT1	B-protein
)	O
phosphorylation	O
induced	O
by	O
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
.	O
Inhibition	O
of	O
IFNgamma	B-protein
receptor-mediated	O
signals	O
by	O
IL-6	B-protein
prevents	O
autoregulation	O
of	O
IFNgamma	O
gene	O
expression	O
by	O
IFNgamma	B-protein
during	O
CD4+	O
T	O
cell	O
activation	O
,	O
thereby	O
preventing	O
Th1	O
differentiation	O
.	O
Thus	O
,	O
IL-6	B-protein
promotes	O
CD4	B-protein
+	O
Th2	O
differentiation	O
and	O
inhibits	O
Th1	O
differentiation	O
by	O
two	O
independent	O
molecular	O
mechanisms	O
.	O
Interaction	O
between	O
CCAAT/enhancer	B-protein
binding	I-protein
protein	I-protein
and	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
1	I-protein
regulates	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
cells	O
of	O
the	O
monocyte/macrophage	O
lineage	O
.	O
Recent	O
observations	O
have	O
shown	O
two	O
CCAAT/enhancer	O
binding	O
protein	O
(	O
C/EBP	O
)	O
binding	O
sites	O
to	O
be	O
critically	O
important	O
for	O
efficient	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
within	O
cells	O
of	O
the	O
monocyte/macrophage	O
lineage	O
,	O
a	O
cell	O
type	O
likely	O
involved	O
in	O
transport	O
of	O
the	O
virus	O
to	O
the	O
brain	O
.	O
Additionally	O
,	O
sequence	O
variation	O
at	O
C/EBP	O
site	O
I	O
,	O
which	O
lies	O
immediately	O
upstream	O
of	O
the	O
distal	O
nuclear	O
factor	O
kappa	O
B	O
site	O
and	O
immediately	O
downstream	O
of	O
a	O
binding	O
site	O
for	O
activating	B-protein
transcription	I-protein
factor	I-protein
(	O
ATF	B-protein
)	O
/	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
,	O
has	O
been	O
shown	O
to	O
affect	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
activity	O
.	O
Given	O
that	O
C/EBP	B-protein
proteins	I-protein
have	O
been	O
shown	O
to	O
interact	O
with	O
many	O
other	O
transcription	B-protein
factors	I-protein
including	O
members	O
of	O
the	O
ATF/CREB	B-protein
family	I-protein
,	O
we	O
proceeded	O
to	O
determine	O
whether	O
an	O
adjacent	O
ATF/CREB	O
binding	O
site	O
could	O
affect	O
C/EBP	B-protein
protein	I-protein
binding	O
to	O
C/EBP	O
site	O
I	O
.	O
Electrophoretic	O
mobility	O
shift	O
analyses	O
indicated	O
that	O
selected	O
ATF/CREB	O
site	O
variants	O
assisted	O
in	O
the	O
recruitment	O
of	O
C/EBP	B-protein
proteins	I-protein
to	O
an	O
adjacent	O
,	O
naturally	O
occurring	O
,	O
low-affinity	O
C/EBP	O
site	O
.	O
This	O
biophysical	O
interaction	O
appears	O
to	O
occur	O
via	O
at	O
least	O
two	O
mechanisms	O
.	O
First	O
,	O
low	O
amounts	O
of	O
CREB-1	B-protein
and	O
C/EBP	B-protein
appear	O
to	O
heterodimerize	O
and	O
bind	O
to	O
a	O
site	O
consisting	O
of	O
a	O
half	O
site	O
from	O
both	O
the	O
ATF/CREB	O
and	O
C/EBP	O
binding	O
sites	O
.	O
In	O
addition	O
,	O
CREB-1	B-protein
homodimers	I-protein
bind	O
to	O
the	O
ATF/CREB	O
site	O
and	O
recruit	O
C/EBP	B-protein
dimers	I-protein
to	O
their	O
cognate	O
weak	O
binding	O
sites	O
.	O
This	O
interaction	O
is	O
reciprocal	O
,	O
since	O
C/EBP	B-protein
dimer	I-protein
binding	O
to	O
a	O
strong	O
C/EBP	O
site	O
leads	O
to	O
enhanced	O
CREB-1	B-protein
recruitment	O
to	O
ATF/CREB	O
sites	O
that	O
are	O
weakly	O
bound	O
by	O
CREB	B-protein
.	O
Sequence	O
variation	O
at	O
both	O
C/EBP	O
and	O
ATF/CREB	O
sites	O
affects	O
the	O
molecular	O
interactions	O
involved	O
in	O
mediating	O
both	O
of	O
these	O
mechanisms	O
.	O
Most	O
importantly	O
,	O
sequence	O
variation	O
at	O
the	O
ATF/CREB	O
binding	O
site	O
affected	O
basal	O
LTR	O
activity	O
as	O
well	O
as	O
LTR	O
function	O
following	O
interleukin-6	B-protein
stimulation	O
,	O
a	O
treatment	O
that	O
leads	O
to	O
increases	O
in	O
C/EBP	O
activation	O
.	O
Thus	O
,	O
HIV-1	O
LTR	O
ATF/CREB	O
binding	O
site	O
sequence	O
variation	O
may	O
modulate	O
cellular	O
signaling	O
at	O
the	O
viral	O
promoter	O
through	O
the	O
C/EBP	O
pathway	O
Selective	O
inhibition	O
of	O
interleukin-4	O
gene	O
expression	O
in	O
human	O
T	O
cells	O
by	O
aspirin	O
.	O
Previous	O
studies	O
indicated	O
that	O
aspirin	O
(	O
acetylsalicylic	O
acid	O
[	O
ASA	O
]	O
)	O
can	O
have	O
profound	O
immunomodulatory	O
effects	O
by	O
regulating	O
cytokine	O
gene	O
expression	O
in	O
several	O
types	O
of	O
cells	O
.	O
This	O
study	O
is	O
the	O
first	O
in	O
which	O
concentrations	O
of	O
ASA	O
in	O
the	O
therapeutic	O
range	O
were	O
found	O
to	O
significantly	O
reduce	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
secretion	O
and	O
RNA	O
expression	O
in	O
freshly	O
isolated	O
and	O
mitogen-primed	O
human	O
CD4+	O
T	O
cells	O
.	O
In	O
contrast	O
,	O
ASA	O
did	O
not	O
affect	O
IL-13	B-protein
,	O
interferon-gamma	B-protein
,	O
and	O
IL-2	B-protein
expression	O
.	O
ASA	O
inhibited	O
IL-4	B-protein
,	O
but	O
not	O
IL-2	B-protein
,	O
promoter-driven	O
chloramphenicol	O
acetyltransferase	O
expression	O
in	O
transiently	O
transfected	O
Jurkat	O
T	O
cells	O
.	O
The	O
structurally	O
unrelated	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
indomethacin	O
and	O
flurbiprofen	O
did	O
not	O
affect	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
,	O
whereas	O
the	O
weak	O
cyclo-oxygenase	O
inhibitor	O
salicylic	O
acid	O
was	O
at	O
least	O
as	O
effective	O
as	O
ASA	O
in	O
inhibiting	O
IL-4	B-protein
expression	O
and	O
promoter	O
activity	O
.	O
The	O
inhibitory	O
effect	O
of	O
ASA	O
on	O
IL-4	O
transcription	O
was	O
not	O
mediated	O
by	O
decreased	O
nuclear	O
expression	O
of	O
the	O
known	O
salicylate	B-protein
target	I-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
and	O
was	O
accompanied	O
by	O
reduced	O
binding	O
of	O
an	O
inducible	O
factor	O
to	O
an	O
IL-4	O
promoter	O
region	O
upstream	O
of	O
,	O
but	O
not	O
overlapping	O
,	O
the	O
NF	O
of	O
activated	O
T	O
cells-	O
and	O
NF-kappaB-binding	O
P1	O
element	O
.	O
It	O
is	O
concluded	O
that	O
anti-inflammatory	O
salicylates	O
,	O
by	O
means	O
of	O
a	O
previously	O
unrecognized	O
mechanism	O
of	O
action	O
,	O
can	O
influence	O
the	O
nature	O
of	O
adaptive	O
immune	O
responses	O
by	O
selectively	O
inhibiting	O
the	O
expression	O
of	O
IL-4	B-protein
,	O
a	O
critical	O
effector	O
of	O
these	O
responses	O
,	O
in	O
CD4+	O
T	O
cells	O
.	O
Molecular	O
and	O
cellular	O
mediators	O
of	O
interleukin-1	B-protein
-dependent	O
acute	O
inflammatory	O
arthritis	O
.	O
OBJECTIVE	O
:	O
To	O
examine	O
the	O
molecular	O
and	O
cellular	O
mechanisms	O
in	O
a	O
model	O
of	O
acute	O
inflammatory	O
monarticular	O
arthritis	O
induced	O
by	O
methylated	B-protein
bovine	I-protein
serum	I-protein
albumin	I-protein
(	O
mBSA	B-protein
)	O
and	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
.	O
METHODS	O
:	O
Mice	O
were	O
injected	O
intraarticularly	O
with	O
mBSA	B-protein
on	O
day	O
0	O
and	O
subcutaneously	O
with	O
recombinant	B-protein
human	I-protein
IL-1beta	I-protein
on	O
days	O
0-2	O
.	O
At	O
day	O
7	O
,	O
knee	O
joints	O
were	O
removed	O
and	O
assessed	O
histologically	O
.	O
Flow	O
cytometry	O
and	O
RNase	O
protection	O
were	O
used	O
to	O
analyze	O
IL-1	B-protein
-dependent	O
events	O
.	O
RESULTS	O
:	O
C57BL/6	O
(	O
B6	O
)	O
,	O
129/Sv	O
,	O
and	O
(	O
B6	O
x	O
129/	O
Sv	O
)	O
F1	O
hybrid	O
mice	O
,	O
all	O
H-2b	O
strains	O
,	O
were	O
susceptible	O
to	O
mBSA	B-protein
/IL-1-induced	O
arthritis	O
,	O
whereas	O
C3H/HeJ	O
(	O
H-2k	O
)	O
mice	O
were	O
not	O
.	O
B6	O
mice	O
lacking	O
T	O
and	O
B	O
cells	O
(	O
RAG1-/-	O
)	O
or	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
antigens	I-protein
(	O
MHCII-/-	O
)	O
,	O
and	O
B6	O
mice	O
treated	O
with	O
a	O
CD4+	B-protein
T	I-protein
cell-depleting	I-protein
monoclonal	I-protein
antibody	I-protein
,	O
were	O
resistant	O
to	O
disease	O
.	O
In	O
contrast	O
,	O
B	O
cell-deficient	O
(	O
muMT/	O
muMT	O
)	O
mice	O
developed	O
arthritis	O
at	O
an	O
incidence	O
and	O
severity	O
similar	O
to	O
that	O
of	O
controls	O
.	O
RelB-deficient	O
(	O
RelB-/-	O
)	O
bone	O
marrow	O
chimeric	O
mice	O
had	O
arthritis	O
that	O
was	O
significantly	O
reduced	O
in	O
incidence	O
and	O
severity	O
.	O
In	O
B6	O
mice	O
,	O
flow	O
cytometry	O
demonstrated	O
an	O
IL-1-dependent	O
leukocyte	O
infiltration	O
into	O
the	O
synovial	O
compartment	O
and	O
RNase	O
protection	O
assays	O
revealed	O
induction	O
of	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
for	O
the	O
chemokines	B-protein
monocyte	B-protein
chemoattractant	I-protein
protein	I-protein
1	I-protein
,	O
macrophage	B-protein
inhibitory	I-protein
protein	I-protein
2	I-protein
(	O
MIP-2	B-protein
)	O
,	O
RANTES	B-protein
,	O
MIP-1alpha	B-protein
,	O
and	O
MIP-1beta	B-protein
,	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
CONCLUSION	O
:	O
Arthritis	O
induced	O
by	O
mBSA	B-protein
/	O
IL-1	B-protein
is	O
strain	O
specific	O
and	O
dependent	O
on	O
CD4+	O
T	O
lymphocytes	O
and	O
at	O
least	O
partially	O
on	O
RelB	B-protein
,	O
but	O
not	O
on	O
B	O
lymphocytes	O
or	O
antibody	B-protein
.	O
IL-1	B-protein
contributes	O
to	O
leukocyte	O
recruitment	O
to	O
the	O
synovium	O
and	O
directly	O
induces	O
chemokine	O
mRNA	O
production	O
by	O
synovial	O
cells	O
.	O
This	O
model	O
of	O
acute	O
monarticular	O
arthritis	O
is	O
particularly	O
suitable	O
for	O
further	O
investigations	O
into	O
cell-mediated	O
immunity	O
in	O
arthritis	O
and	O
the	O
role	O
of	O
IL-1	B-protein
.	O
Positive	O
and	O
negative	O
regulation	O
of	O
granulopoiesis	O
by	O
endogenous	B-protein
RARalpha	I-protein
.	O
Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
always	O
associated	O
with	O
chromosomal	O
translocations	O
that	O
disrupt	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RARalpha	O
)	O
gene	O
.	O
Whether	O
these	O
translocations	O
relate	O
to	O
a	O
role	O
for	O
endogenous	B-protein
RARalpha	I-protein
in	O
normal	O
granulopoiesis	O
remains	O
uncertain	O
because	O
most	O
studies	O
addressing	O
this	O
question	O
have	O
used	O
non-physiological	O
overexpression	O
systems	O
.	O
Granulocyte	O
differentiation	O
in	O
cells	O
derived	O
from	O
RARalpha-deficient	O
(	O
RARalpha	O
(	O
-/-	O
)	O
)	O
mice	O
was	O
studied	O
and	O
evaluated	O
in	O
the	O
context	O
of	O
agonist-bound	B-protein
and	I-protein
ligand-free	I-protein
RARalpha	I-protein
.	O
Our	O
results	O
demonstrate	O
that	O
RARalpha	B-protein
is	O
dispensable	O
for	O
granulopoiesis	O
,	O
as	O
RARalpha	O
(	O
-/-	O
)	O
mice	O
have	O
a	O
normal	O
granulocyte	O
population	O
despite	O
an	O
impaired	O
ability	O
to	O
respond	O
to	O
retinoids	O
.	O
However	O
,	O
although	O
it	O
is	O
not	O
absolutely	O
required	O
,	O
RARalpha	B-protein
can	O
bidirectionally	O
modulate	O
granulopoiesis	O
.	O
RARalpha	B-protein
stimulates	O
differentiation	O
in	O
response	O
to	O
exogenous	O
retinoic	O
acid	O
.	O
Furthermore	O
,	O
endogenous	O
retinoids	O
control	O
granulopoiesis	O
in	O
vivo	O
,	O
as	O
either	O
vitamin	O
A-deficient	O
mice	O
or	O
animals	O
treated	O
with	O
an	O
RAR	O
antagonist	O
accumulate	O
more	O
immature	O
granulocytes	O
in	O
their	O
bone	O
marrow	O
.	O
Conversely	O
,	O
RARalpha	B-protein
acts	O
to	O
limit	O
differentiation	O
in	O
the	O
absence	O
of	O
ligand	B-protein
because	O
granulocyte	O
precursors	O
from	O
RARalpha	O
(	O
-/-	O
)	O
mice	O
differentiate	O
earlier	O
in	O
culture	O
.	O
Thus	O
,	O
the	O
block	O
in	O
granulopoiesis	O
exerted	O
by	O
RARalpha	B-protein
fusion	B-protein
proteins	I-protein
expressed	O
in	O
APL	O
cells	O
may	O
correspond	O
to	O
an	O
amplification	O
of	O
a	O
normal	O
function	O
of	O
unliganded	B-protein
RARalpha	I-protein
.	O
Expression	O
and	O
function	O
of	O
a	O
stem	O
cell	O
promoter	O
for	O
the	O
murine	O
CBFalpha2	O
gene	O
:	O
distinct	O
roles	O
and	O
regulation	O
in	O
natural	O
killer	O
and	O
T	O
cell	O
development	O
.	O
The	O
Runt	B-protein
family	I-protein
transcription	I-protein
factor	I-protein
CBFalpha2	B-protein
(	O
AML1	B-protein
,	O
PEBP2alphaB	B-protein
,	O
or	O
Runx1	B-protein
)	O
is	O
required	O
by	O
hematopoietic	O
stem	O
cells	O
and	O
expressed	O
at	O
high	O
levels	O
in	O
T-lineage	O
cells	O
.	O
In	O
human	O
T	O
cells	O
CBFalpha2	B-protein
is	O
usually	O
transcribed	O
from	O
a	O
different	O
promoter	O
(	O
distal	O
promoter	O
)	O
than	O
in	O
myeloid	O
cells	O
(	O
proximal	O
promoter	O
)	O
,	O
but	O
the	O
developmental	O
and	O
functional	O
significance	O
of	O
this	O
promoter	O
switch	O
has	O
not	O
been	O
known	O
.	O
Here	O
,	O
we	O
report	O
that	O
both	O
coding	O
and	O
noncoding	O
sequences	O
of	O
the	O
distal	O
5	O
'	O
end	O
are	O
highly	O
conserved	O
between	O
the	O
human	O
and	O
the	O
murine	O
genes	O
,	O
and	O
the	O
distal	O
promoter	O
is	O
responsible	O
for	O
the	O
overwhelming	O
majority	O
of	O
CBFalpha2	O
expression	O
in	O
murine	O
hematopoietic	O
stem	O
cells	O
as	O
well	O
as	O
in	O
T	O
cells	O
.	O
Distal	O
promoter	O
activity	O
is	O
maintained	O
throughout	O
T	O
cell	O
development	O
and	O
at	O
lower	O
levels	O
in	O
B	O
cell	O
development	O
,	O
but	O
downregulated	O
in	O
natural	O
killer	O
cell	O
development	O
.	O
The	O
distal	O
N-terminal	O
isoform	O
binds	O
to	O
functionally	O
important	O
regulatory	O
sites	O
from	O
known	O
target	O
genes	O
with	O
two-	O
to	O
threefold	O
higher	O
affinity	O
than	O
the	O
proximal	O
N-terminal	O
isoform	O
.	O
Neither	O
full-length	O
isoform	O
alters	O
growth	O
of	O
a	O
myeloid	O
cell	O
line	O
under	O
nondifferentiating	O
conditions	O
,	O
but	O
the	O
proximal	O
isoform	O
selectively	O
delays	O
mitotic	O
arrest	O
of	O
the	O
cell	O
line	O
under	O
differentiating	O
conditions	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
greater	O
numbers	O
of	O
neutrophils	O
.	O
Constitutive	O
PI3-K	O
activity	O
is	O
essential	O
for	O
proliferation	O
,	O
but	O
not	O
survival	O
,	O
of	O
Theileria	O
parva-transformed	O
B	O
cells	O
.	O
Theileria	O
is	O
an	O
intracellular	O
parasite	O
that	O
causes	O
lymphoproliferative	O
disorders	O
in	O
cattle	O
,	O
and	O
infection	O
of	O
leucocytes	O
induces	O
a	O
transformed	O
phenotype	O
similar	O
to	O
tumour	O
cells	O
,	O
but	O
the	O
mechanisms	O
by	O
which	O
the	O
parasite	O
induces	O
this	O
phenotype	O
are	O
not	O
understood	O
.	O
Here	O
,	O
we	O
show	O
that	O
infected	O
B	O
lymphocytes	O
display	O
constitutive	O
phosphoinositide	O
3-kinase	O
(	O
PI3-K	O
)	O
activity	O
,	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
proliferation	O
,	O
but	O
not	O
survival	O
.	O
Importantly	O
,	O
we	O
demonstrate	O
that	O
one	O
mechanism	O
by	O
which	O
PI3-K	B-protein
mediates	O
the	O
proliferation	O
of	O
infected	O
B	O
lymphocytes	O
is	O
through	O
the	O
induction	O
of	O
a	O
granulocyte-monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
-dependent	O
autocrine	O
loop	O
.	O
PI3-K	B-protein
induction	O
of	O
GM-CSF	B-protein
appears	O
to	O
be	O
at	O
the	O
transcriptional	O
level	O
and	O
,	O
consistently	O
,	O
we	O
demonstrate	O
that	O
PI3-K	B-protein
is	O
also	O
involved	O
in	O
the	O
constitutive	O
induction	O
of	O
AP-1	B-protein
and	O
NF-kappaB	B-protein
,	O
which	O
characterizes	O
Theileria-infected	O
leucocytes	O
.	O
Taken	O
together	O
,	O
our	O
results	O
highlight	O
a	O
novel	O
strategy	O
exploited	O
by	O
the	O
intracellular	O
parasite	O
Theileria	O
to	O
induce	O
continued	O
proliferation	O
of	O
its	O
host	O
leucocyte	O
.	O
Lymphokine	B-protein
dependence	O
of	O
STAT3	O
activation	O
produced	O
by	O
surface	O
immunoglobulin	O
cross-linking	O
and	O
by	O
phorbol	O
ester	O
plus	O
calcium	O
ionophore	O
treatment	O
in	O
B	O
cells	O
.	O
Stimulation	O
of	O
B	O
cells	O
by	O
surface	B-protein
immunoglobulin	I-protein
(	O
sIg	B-protein
)	O
triggering	O
,	O
or	O
through	O
the	O
mitogenic	O
combination	O
of	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
,	O
is	O
accompanied	O
by	O
activation	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O
The	O
mechanism	O
responsible	O
for	O
the	O
delayed	O
nuclear	O
accumulation	O
of	O
phosphorylated	B-protein
STAT3	I-protein
was	O
examined	O
in	O
detail	O
,	O
focusing	O
on	O
the	O
role	O
of	O
B	B-protein
cell-derived	I-protein
lymphokines	I-protein
.	O
sIg	B-protein
-induced	O
activation	O
of	O
STAT3	B-protein
was	O
partially	O
inhibited	O
in	O
B	O
cells	O
obtained	O
from	O
IL-6-	O
or	O
IL-10-deficient	O
mice	O
,	O
and	O
was	O
partially	O
blocked	O
by	O
neutralizing	B-protein
antibodies	I-protein
directed	O
against	O
either	O
of	O
these	O
lymphokines	B-protein
.	O
sIg	B-protein
-induced	O
STAT3	O
activation	O
was	O
completely	O
inhibited	O
by	O
combining	O
IL-6-	B-protein
and	I-protein
IL-10-specific	I-protein
neutralizing	I-protein
antibodies	I-protein
,	O
or	O
by	O
adding	O
individual	O
neutralizing	B-protein
antibodies	I-protein
to	O
B	O
cells	O
obtained	O
from	O
lymphokine-deficient	O
animals	O
.	O
In	O
contrast	O
,	O
IL-10	B-protein
alone	O
appeared	O
to	O
account	O
for	O
STAT3	O
activation	O
resulting	O
from	O
B	O
cell	O
stimulation	O
with	O
phorbol	O
ester	O
and	O
calcium	O
ionophore	O
.	O
In	O
keeping	O
with	O
these	O
results	O
,	O
soluble	O
IL-6	B-protein
and	O
IL-10	B-protein
were	O
found	O
in	O
supernatant	O
fluid	O
obtained	O
from	O
stimulated	O
B	O
cells	O
.	O
This	O
work	O
indicates	O
that	O
a	O
lymphokine	O
pathway	O
is	O
responsible	O
for	O
STAT3	O
activation	O
that	O
occurs	O
late	O
after	O
B	O
cell	O
stimulation	O
,	O
and	O
points	O
out	O
differences	O
in	O
B	O
cell	O
activation	O
that	O
result	O
from	O
stimulation	O
through	O
the	O
antigen	B-protein
receptor	I-protein
and	O
through	O
pharmacological	O
mimicry	O
of	O
signaling	B-protein
mediators	I-protein
.	O
Transcription	B-protein
factor	I-protein
AP-4	I-protein
is	O
a	O
ligand	B-protein
for	O
immunoglobulin-kappa	O
promoter	O
E-box	O
elements	O
.	O
Immunoglobulin	O
(	O
Ig	O
)	O
-kappa	O
promoters	O
from	O
humans	O
and	O
mice	O
share	O
conserved	O
sequences	O
.	O
The	O
octamer	O
element	O
is	O
common	O
to	O
all	O
Ig	O
promoters	O
and	O
pivotal	O
for	O
their	O
function	O
.	O
However	O
,	O
other	O
conserved	O
sequence	O
motifs	O
,	O
that	O
differ	O
between	O
Ig	O
variable	O
gene	O
families	O
,	O
are	O
required	O
for	O
normal	O
promoter	O
function	O
.	O
These	O
conserved	O
motifs	O
do	O
not	O
stimulate	O
transcription	O
in	O
the	O
absence	O
of	O
an	O
octamer	O
.	O
One	O
example	O
is	O
an	O
E-box	O
of	O
the	O
E47/E12	O
type	O
(	O
5'-CAGCTG-3	O
'	O
)	O
,	O
which	O
is	O
found	O
in	O
all	O
promoters	O
of	O
the	O
human	O
and	O
murine	O
Ig-kappa	O
gene	O
subgroups/families	O
,	O
with	O
the	O
exception	O
of	O
subgroups	O
II	O
and	O
VI	O
and	O
their	O
related	O
murine	O
families	O
.	O
In	O
the	O
present	O
study	O
we	O
show	O
that	O
the	O
ubiquitously	O
expressed	O
transcription	B-protein
factor	I-protein
AP-4	I-protein
,	O
and	O
not	O
E47	B-protein
,	O
interacts	O
specifically	O
with	O
the	O
kappa	O
promoter	O
E-boxes	O
when	O
tested	O
in	O
electrophoretic	O
mobility-shift	O
assays	O
using	O
nuclear	O
extracts	O
derived	O
from	O
human	O
and	O
murine	O
B-cell	O
lines	O
.	O
Furthermore	O
,	O
AP-4	B-protein
,	O
unlike	O
E47	B-protein
,	O
did	O
not	O
act	O
as	O
a	O
transactivator	B-protein
,	O
which	O
is	O
in	O
agreement	O
with	O
previous	O
studies	O
on	O
intact	O
kappa	O
promoters	O
,	O
showing	O
that	O
transcription	O
is	O
absent	O
when	O
the	O
octamer	O
element	O
has	O
been	O
mutated	O
.	O
Based	O
on	O
these	O
data	O
,	O
and	O
the	O
conservation	O
of	O
the	O
5'-CAGCTG-3	O
'	O
motif	O
among	O
human	O
and	O
murine	O
kappa	O
promoters	O
,	O
we	O
propose	O
that	O
AP-4	B-protein
is	O
the	O
major	B-protein
ligand	I-protein
for	O
Ig-kappa	O
promoter	O
E-boxes	O
.	O
A	O
16-mer	O
peptide	O
(	O
RQIKIWFQNRRMKWKK	O
)	O
from	O
antennapedia	O
preferentially	O
targets	O
the	O
Class	O
I	O
pathway	O
.	O
Translocation	O
of	O
antigenic	O
peptides	O
into	O
the	O
cytosol	O
of	O
antigen	O
presenting	O
cells	O
facilitates	O
proteosomal	O
processing	O
and	O
loading	O
into	O
Class	B-protein
I	I-protein
molecules	I-protein
for	O
MHC	O
presentation	O
on	O
the	O
cell	O
surface	O
.	O
The	O
DNA	B-protein
binding	I-protein
domain	I-protein
of	O
the	O
Drosophila	B-protein
transcription	I-protein
factor	I-protein
(	O
Antennapedia	B-protein
)	O
,	O
a	O
60	B-protein
amino	I-protein
acid	I-protein
protein	I-protein
,	O
is	O
rapidly	O
taken	O
up	O
by	O
cells	O
and	O
has	O
been	O
fused	O
to	O
selected	O
antigens	B-protein
to	O
enhance	O
their	O
immunogenicity	O
.	O
We	O
now	O
demonstrate	O
that	O
a	O
16	O
amino	O
acid	O
peptide	O
from	O
antennapedia	O
can	O
facilitate	O
the	O
cytoplasmic	O
uptake	O
of	O
CTL	O
epitope	O
9-mer	O
peptides	O
.	O
Synthetic	O
peptides	O
were	O
made	O
containing	O
the	O
16-mer	O
antennapedia	O
peptide	O
linked	O
in	O
tandem	O
to	O
the	O
ovalbumin	O
SIINFEKL	O
CTL	O
peptide	O
.	O
The	O
peptide	O
complex	O
was	O
shown	O
to	O
rapidly	O
internalise	O
into	O
APCs	O
by	O
confocal	O
microscopy	O
.	O
This	O
peptide	O
induced	O
CTL	O
in	O
C57BL/6	O
mice	O
and	O
protected	O
them	O
against	O
growth	O
of	O
an	O
ovalbumin	O
expressing	O
tumour	O
cell	O
line	O
(	O
E.G7-OVA	O
)	O
.	O
The	O
ability	O
of	O
the	O
hybrid	O
peptide	O
to	O
be	O
processed	O
and	O
presented	O
by	O
APCs	O
was	O
similar	O
,	O
whether	O
the	O
SIINFEKL	O
sequence	O
was	O
appended	O
at	O
the	O
C-terminus	B-protein
or	O
N-terminus	B-protein
of	O
the	O
Antennapedia	O
peptide	O
.	O
The	O
production	O
of	O
synthetic	O
peptides	O
containing	O
other	O
CTL	O
peptide	O
epitopes	O
may	O
be	O
useful	O
for	O
priming	O
CTLs	O
in	O
vitro	O
and	O
in	O
vivo	O
Bone	O
marrow	O
cells	O
promote	O
TH2	O
polarization	O
and	O
inhibit	O
virus-specific	O
CTL	O
generation	O
.	O
This	O
laboratory	O
recently	O
reported	O
that	O
human	O
bone	O
marrow	O
cells	O
(	O
BMC	O
)	O
inhibit	O
the	O
generation	O
of	O
virus-specific	O
CTL	O
in	O
culture	O
.	O
The	O
culture	O
supernatants	O
contained	O
increased	O
levels	O
of	O
prostaglandin	B-protein
E	I-protein
(	I-protein
2	I-protein
)	I-protein
(	I-protein
PGE	I-protein
(	I-protein
2	I-protein
)	I-protein
)	I-protein
(	O
shown	O
to	O
favor	O
TH2	O
cell	O
development	O
)	O
and	O
also	O
inhibited	O
EBV-CTL	O
effector	O
cell	O
development	O
.	O
In	O
this	O
study	O
,	O
we	O
obtained	O
PBL	O
from	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
IgG	B-protein
antibody	I-protein
positive	O
kidney	O
transplant	O
recipients	O
(	O
R	O
)	O
and	O
their	O
living-related	O
donors	O
(	O
LRD	O
)	O
one	O
year	O
after	O
renal	O
transplantation	O
.	O
EBV-specific	O
CTL	O
were	O
then	O
generated	O
in	O
vitro	O
by	O
stimulating	O
PBL	O
with	O
autologous	O
EBV-transformed	O
B	O
cells	O
(	O
EBV-B	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
autologous	O
BMC	O
.	O
The	O
addition	O
of	O
BMC	O
to	O
the	O
EBV-CTL	O
generation	O
cultures	O
increased	O
the	O
intracellular	O
expression	O
in	O
CD3+	O
cells	O
of	O
IL-4	B-protein
,	I-protein
-5	I-protein
,	I-protein
-6	I-protein
,	I-protein
-10	I-protein
,	I-protein
and	I-protein
-13	I-protein
.	O
These	O
CD3+	O
cells	O
also	O
expressed	O
increased	O
levels	O
of	O
the	O
TH2	B-protein
associated	I-protein
receptor	I-protein
CCR3	I-protein
.	O
Inhibition	O
was	O
even	O
observed	O
by	O
preparing	O
EBV-CTL	O
generating	O
cultures	O
in	O
trans-wells	O
that	O
separated	O
the	O
autologous	O
BMC	O
from	O
the	O
PBL	O
+	O
EBV-B	O
.	O
It	O
was	O
then	O
observed	O
that	O
CD3+	O
cells	O
obtained	O
after	O
7	O
days	O
of	O
culture	O
in	O
the	O
presence	O
of	O
autologous	O
BMC	O
could	O
be	O
used	O
as	O
inhibitors	O
of	O
EBV-CTL	O
generation	O
.	O
Protein	B-protein
Kinase	I-protein
A	I-protein
(	O
PKA	B-protein
)	O
,	O
a	O
cAMP	B-protein
kinase	I-protein
that	O
is	O
involved	O
in	O
the	O
upregulation	O
of	O
TH2	B-protein
cytokine	I-protein
activity	O
,	O
was	O
increased	O
in	O
EBV-CTL	O
cultures	O
by	O
the	O
presence	O
of	O
BMC	O
.	O
Additionally	O
,	O
IL-4-mediated	O
signal	O
transduction	O
and	O
activation	O
of	O
transcription	O
(	O
STAT-6	B-protein
)	O
phosphorylation	O
was	O
slightly	O
increased	O
.	O
These	O
results	O
show	O
that	O
the	O
BMC	O
inhibition	O
is	O
mediated	O
by	O
soluble	B-protein
factors	I-protein
(	O
cytokines	B-protein
)	O
and	O
that	O
cell-cell	O
contact	O
in	O
this	O
autologous	O
system	O
is	O
not	O
required	O
,	O
so	O
that	O
BMC	O
(	O
at	O
least	O
partially	O
,	O
via	O
cytokine	O
production	O
)	O
promote	O
TH2	O
polarization	O
in	O
culture	O
.	O
Moreover	O
,	O
TH2	O
cells	O
induced	O
by	O
culturing	O
with	O
autologous	O
BMC	O
directly	O
inhibit	O
EBV-CTL	O
generation	O
,	O
and	O
TH2	B-protein
associated	O
PKA	B-protein
,	O
CCR3	B-protein
,	O
and	O
STAT-6	B-protein
phosphorylation	O
are	O
enhanced	O
by	O
BMC	O
.	O
Reduction	O
in	O
DNA	O
binding	O
activity	O
of	O
the	O
transcription	B-protein
factor	I-protein
Pax-5a	B-protein
in	O
B	O
lymphocytes	O
of	O
aged	O
mice	O
.	O
Aging	O
has	O
been	O
associated	O
with	O
intrinsic	O
changes	O
of	O
the	O
humoral	O
immune	O
response	O
,	O
which	O
may	O
lead	O
to	O
an	O
increased	O
occurrence	O
of	O
autoimmune	O
disorders	O
and	O
pathogenic	O
susceptibility	O
.	O
The	O
transcription	B-protein
factor	I-protein
Pax-5	B-protein
is	O
a	O
key	O
regulator	O
of	O
B	O
cell	O
development	O
.	O
Pax-5a/B	B-protein
cell-specific	I-protein
activator	I-protein
protein	I-protein
and	O
an	O
alternatively	B-protein
spliced	I-protein
isoform	I-protein
,	I-protein
Pax-5d	I-protein
,	O
may	O
have	O
opposing	O
functions	O
in	O
transcriptional	O
regulation	O
due	O
to	O
the	O
lack	O
of	O
a	O
transactivation	B-protein
domain	I-protein
in	O
Pax-5d	B-protein
.	O
To	O
study	O
B	O
cell	O
-specific	O
changes	O
that	O
occur	O
during	O
the	O
aging	O
process	O
,	O
we	O
investigated	O
expression	O
patterns	O
of	O
Pax-5a	B-protein
and	I-protein
5d	I-protein
in	O
mature	O
B	O
cells	O
of	O
young	O
and	O
aged	O
mice	O
.	O
RNase	O
protection	O
assays	O
showed	O
a	O
similar	O
transcriptional	O
pattern	O
for	O
both	O
age	O
groups	O
that	O
indicates	O
that	O
aging	O
has	O
no	O
affect	O
on	O
transcription	O
initiation	O
or	O
alternative	O
splicing	O
for	O
either	O
isoform	B-protein
.	O
In	O
contrast	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
Pax-5a	B-protein
but	O
not	O
Pax-5d	B-protein
protein	O
was	O
observed	O
in	O
aged	O
B	O
cells	O
in	O
vitro	O
,	O
while	O
Western	O
blot	O
analyses	O
showed	O
that	O
similar	O
levels	O
of	O
Pax-5a	B-protein
and	I-protein
5d	I-protein
proteins	O
were	O
present	O
in	O
both	O
age	O
groups	O
.	O
The	O
observed	O
decrease	O
in	O
Pax-5a	B-protein
binding	O
activity	O
correlated	O
with	O
changes	O
in	O
expression	O
of	O
two	O
Pax-5	O
target	O
genes	O
in	O
aged	O
B	O
cells	O
.	O
Expression	O
of	O
the	O
Ig	B-protein
J	I-protein
chain	I-protein
and	O
the	O
secreted	O
form	O
of	O
Ig	B-protein
mu	I-protein
,	O
which	O
are	O
both	O
known	O
to	O
be	O
suppressed	O
by	O
Pax-5a	B-protein
in	O
mature	O
B	O
cells	O
,	O
were	O
increased	O
in	O
B	O
cells	O
of	O
aged	O
mice	O
.	O
Together	O
,	O
our	O
studies	O
suggest	O
that	O
changes	O
associated	O
with	O
the	O
aging	O
phenotype	O
cause	O
posttranslational	O
modification	O
(	O
s	O
)	O
of	O
Pax-5a	B-protein
but	O
not	O
Pax-5d	B-protein
,	O
which	O
may	O
lead	O
to	O
an	O
abnormal	O
B	O
cell	O
phenotype	O
in	O
aged	O
mice	O
,	O
associated	O
with	O
elevated	O
levels	O
of	O
J	B-protein
chain	I-protein
,	O
and	O
secretion	O
of	O
IgM	B-protein
NF-kappa	B-protein
B/Rel	I-protein
participation	O
in	O
the	O
lymphokine-dependent	O
proliferation	O
of	O
T	O
lymphoid	O
cells	O
.	O
Proliferative	O
responses	O
of	O
lymphoid	O
cells	O
to	O
IL-2	B-protein
and	O
IL-4	B-protein
depend	O
on	O
activation	O
of	O
the	O
cells	O
,	O
but	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
activation	O
enhances	O
cellular	O
competence	O
to	O
respond	O
to	O
cytokines	B-protein
is	O
not	O
fully	O
understood	O
.	O
The	O
NF-kappaB/Rel	B-protein
family	I-protein
represents	O
one	O
signal	O
transduction	O
pathway	O
induced	O
during	O
such	O
activation	O
.	O
We	O
show	O
in	O
this	O
study	O
that	O
inhibition	O
of	O
NF-kappaB	B-protein
through	O
the	O
expression	O
of	O
an	O
IkappaBalpha	B-protein
(	O
inhibitory	B-protein
protein	I-protein
that	O
dissociates	O
from	O
NF-kappaB	B-protein
)	O
mutant	O
refractory	O
to	O
signal-induced	O
degradation	O
(	O
IkappaBalpha	B-protein
(	I-protein
DeltaN	I-protein
)	I-protein
)	O
interfered	O
with	O
the	O
acquisition	O
of	O
competence	O
to	O
proliferate	O
in	O
response	O
to	O
IL-4	B-protein
as	O
well	O
as	O
IL-2	B-protein
.	O
Thymocytes	O
and	O
T	O
cells	O
from	O
IkappaBalpha	B-protein
(	I-protein
DeltaN	I-protein
)	I-protein
transgenic	O
mice	O
expressed	O
normal	O
levels	O
of	O
IL-2R	B-protein
subunits	I-protein
.	O
However	O
,	O
transgenic	O
cells	O
exhibited	O
a	O
dramatic	O
defect	O
in	O
Stat5A	O
activation	O
treatment	O
with	O
IL-2	B-protein
,	O
and	O
a	O
similar	O
defect	O
was	O
observed	O
for	O
IL-4	B-protein
-induced	O
Stat5	B-protein
.	O
In	O
contrast	O
,	O
T	O
lymphoid	O
cells	O
with	O
inhibition	O
of	O
NF-kappaB	B-protein
showed	O
normal	O
insulin	O
receptor	O
substrate-2	O
phosphorylation	O
and	O
only	O
a	O
modest	O
decrease	O
in	O
Stat6	O
activation	O
and	O
insulin	O
receptor	O
substrate-1	O
phosphorylation	O
after	O
IL-4	O
stimulation	O
.	O
These	O
results	O
indicate	O
that	O
the	O
NF-kappaB/Rel/IkappaBalpha	O
system	O
can	O
regulate	O
cytokine	B-protein
receptor	I-protein
capacitation	O
through	O
effects	O
on	O
the	O
induction	O
of	O
downstream	O
signaling	O
by	O
the	O
Stat	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O
BMS-189453	O
,	O
a	O
novel	O
retinoid	O
receptor	O
antagonist	O
,	O
is	O
a	O
potent	O
testicular	O
toxin	O
.	O
BMS-189453	O
is	O
a	O
synthetic	O
retinoid	O
that	O
acts	O
as	O
an	O
antagonist	O
at	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
alpha	I-protein
,	I-protein
beta	I-protein
,	I-protein
and	I-protein
gamma	I-protein
.	O
In	O
Sprague	O
Dawley	O
rats	O
at	O
daily	O
oral	O
doses	O
of	O
15	O
,	O
60	O
,	O
or	O
240	O
mg/kg	O
for	O
1	O
month	O
,	O
BMS-189453	O
produced	O
increases	O
in	O
leukocyte	O
counts	O
,	O
alkaline	B-protein
phosphatase	I-protein
and	O
alanine	B-protein
aminotransferase	I-protein
levels	O
,	O
and	O
marked	O
testicular	O
degeneration	O
and	O
atrophy	O
at	O
all	O
doses	O
.	O
Significant	O
overt	O
signs	O
of	O
toxicity	O
and	O
deaths	O
occurred	O
at	O
240	O
mg/kg	O
,	O
whereas	O
body-weight	O
and	O
food-consumption	O
decreases	O
occurred	O
at	O
60	O
and	O
240	O
mg/kg	O
.	O
When	O
BMS-189453	O
was	O
administered	O
to	O
male	O
rats	O
at	O
daily	O
doses	O
ranging	O
from	O
12.5	O
to	O
100	O
mg/kg	O
for	O
1	O
week	O
,	O
only	O
minimal	O
testicular	O
changes	O
occurred	O
at	O
all	O
doses	O
,	O
shortly	O
after	O
the	O
dosing	O
period	O
.	O
However	O
,	O
after	O
a	O
1-month	O
drug-free	O
observation	O
period	O
,	O
marked	O
testicular	O
atrophy	O
was	O
evident	O
at	O
all	O
doses	O
.	O
BMS-189453	O
was	O
then	O
administered	O
at	O
doses	O
of	O
2	O
,	O
10	O
,	O
or	O
50	O
mg/kg	O
to	O
male	O
rats	O
for	O
1	O
,	O
3	O
,	O
or	O
7	O
consecutive	O
days	O
.	O
Dose-	O
and	O
duration-dependent	O
testicular	O
toxicity	O
that	O
occurred	O
after	O
a	O
1-month	O
observation	O
period	O
did	O
not	O
recover	O
,	O
and	O
,	O
in	O
some	O
cases	O
,	O
was	O
more	O
severe	O
4	O
months	O
after	O
the	O
last	O
dose	O
.	O
In	O
rabbits	O
administered	O
BMS-189453	O
at	O
oral	O
doses	O
of	O
2	O
,	O
10	O
,	O
or	O
50	O
mg/kg	O
for	O
1	O
week	O
,	O
testicular	O
degeneration	O
and	O
atrophy	O
were	O
evident	O
in	O
the	O
high-dose	O
group	O
at	O
1	O
month	O
following	O
treatment	O
.	O
These	O
studies	O
indicate	O
that	O
retinoid	O
antagonists	O
can	O
selectively	O
produce	O
progressive	O
and	O
prolonged	O
testicular	O
toxicity	O
after	O
single	O
or	O
repeated	O
oral	O
doses	O
that	O
are	O
otherwise	O
well	O
tolerated	O
.	O
Sequential	O
involvement	O
of	O
NFAT	B-protein
and	O
Egr	B-protein
transcription	B-protein
factors	I-protein
in	O
FasL	O
regulation	O
.	O
The	O
critical	O
function	O
of	O
NFAT	B-protein
proteins	I-protein
in	O
maintaining	O
lymphoid	O
homeostasis	O
was	O
revealed	O
in	O
mice	O
lacking	O
both	O
NFATp	B-protein
and	O
NFAT4	B-protein
(	O
DKO	O
)	O
.	O
DKO	O
mice	O
exhibit	O
increased	O
lymphoproliferation	O
,	O
decreased	O
activation-induced	O
cell	O
death	O
,	O
and	O
impaired	O
induction	O
of	O
FasL	B-protein
.	O
The	O
transcription	B-protein
factors	I-protein
Egr2	B-protein
and	O
Egr3	B-protein
are	O
potent	O
activators	O
of	O
FasL	O
expression	O
.	O
Here	O
we	O
find	O
that	O
Egr2	O
and	O
Egr3	O
are	O
NFAT	O
target	O
genes	O
.	O
Activation	O
of	O
FasL	B-protein
occurs	O
via	O
the	O
NFAT	B-protein
-dependent	O
induction	O
of	O
Egr3	O
,	O
as	O
demonstrated	O
by	O
the	O
ability	O
of	O
exogenously	O
provided	O
NFATp	B-protein
to	O
restore	O
Egr	B-protein
-dependent	O
FasL	O
promoter	O
activity	O
in	O
DKO	O
lymph	O
node	O
cells	O
.	O
Further	O
,	O
Egr3	O
expression	O
is	O
enriched	O
in	O
Th1	O
cells	O
,	O
suggesting	O
a	O
molecular	O
basis	O
for	O
the	O
known	O
preferential	O
expression	O
of	O
FasL	B-protein
in	O
the	O
Th1	O
versus	O
Th2	O
subset	O
.	O
Mechanisms	O
and	O
clinical	O
relevance	O
of	O
nongenomic	O
glucocorticoid	O
actions	O
.	O
Glucocorticoids	O
have	O
profound	O
anti-inflammatory	O
and	O
immunosuppressive	O
actions	O
when	O
used	O
therapeutically	O
.	O
The	O
therapeutic	O
dose	O
is	O
quite	O
variable	O
and	O
depends	O
on	O
the	O
disease	O
,	O
but	O
ranges	O
from	O
very	O
low	O
to	O
extremely	O
high	O
.	O
The	O
rationale	O
for	O
the	O
use	O
of	O
various	O
dosage	O
regimens	O
for	O
specific	O
clinical	O
indications	O
is	O
the	O
existence	O
of	O
three	O
distinct	O
,	O
therapeutically	O
relevant	O
effects	O
:	O
genomic	O
,	O
specific	O
nongenomic	O
and	O
unspecific	O
nongenomic	O
.	O
Genomic	O
effects	O
are	O
mediated	O
by	O
cytosolic	B-protein
receptors	I-protein
that	O
alter	O
expression	O
of	O
specific	O
genes	O
.	O
Specific	O
nongenomic	O
effects	O
occur	O
within	O
a	O
few	O
minutes	O
and	O
are	O
mediated	O
by	O
steroid-selective	B-protein
membrane	I-protein
receptors	I-protein
.	O
Unspecific	O
nongenomic	O
effects	O
occur	O
within	O
seconds	O
,	O
but	O
only	O
at	O
high	O
glucocorticoid	O
dosages	O
,	O
and	O
seem	O
to	O
result	O
from	O
direct	O
interactions	O
with	O
biological	O
membranes	O
.	O
For	O
unspecific	O
nongenomic	O
effects	O
,	O
methylprednisolone	O
and	O
other	O
glucocorticoids	O
have	O
been	O
shown	O
to	O
inhibit	O
cation	O
cycling	O
across	O
the	O
plasma	O
membrane	O
,	O
but	O
to	O
have	O
little	O
effect	O
on	O
protein	O
synthesis	O
.	O
Thus	O
,	O
glucocorticoids	O
could	O
diminish	O
or	O
prevent	O
the	O
acute	O
immune	O
response	O
by	O
interfering	O
with	O
processes	O
such	O
as	O
the	O
rise	O
in	O
intracellular	O
Ca2+	O
concentration	O
.	O
It	O
is	O
proposed	O
that	O
the	O
additional	O
therapeutic	O
benefit	O
of	O
higher	O
doses	O
is	O
obtained	O
via	O
these	O
nongenomic	O
effects	O
.	O
High	O
glucose-induced	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
expression	O
through	O
an	O
osmotic	O
effect	O
in	O
rat	O
mesangial	O
cells	O
is	O
PKC-NF-kappa	O
B-dependent	O
.	O
AIMS/HYPOTHESIS	O
:	O
Infiltration	O
of	O
mononuclear	O
cells	O
and	O
glomerular	O
enlargement	O
accompanied	O
by	O
glomerular	O
cell	O
proliferation	O
are	O
very	O
early	O
characteristics	O
of	O
the	O
pathophysiology	O
of	O
diabetes	O
.	O
To	O
clarify	O
the	O
mechanism	O
of	O
early	O
diabetic	O
nephropathy	O
,	O
we	O
measured	O
[	O
3H	O
]	O
-thymidine	O
incorporation	O
and	O
cell	O
numbers	O
to	O
show	O
the	O
influence	O
of	O
a	O
high	O
ambient	O
glucose	O
concentration	O
and	O
the	O
osmotic	O
effect	O
on	O
rat	O
mesangial	O
cell	O
proliferation	O
.	O
We	O
also	O
measured	O
the	O
effect	O
of	O
high	O
glucose	O
on	O
the	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
by	O
flow	O
cytometry	O
and	O
semiquantitative	O
RT-PCR	O
in	O
mesangial	O
cells	O
and	O
the	O
adhesion	O
of	O
leukocytes	O
to	O
mesangial	O
cells	O
.	O
METHODS/RESULTS	O
:	O
Cells	O
exposed	O
to	O
high	O
D-glucose	O
(	O
30	O
mmol/l	O
)	O
caused	O
an	O
increase	O
in	O
[	O
3H	O
]	O
-thymidine	O
incorporation	O
and	O
cell	O
numbers	O
at	O
24	O
and	O
48	O
h	O
and	O
normalized	O
at	O
72	O
h	O
(	O
p	O
<	O
0.05	O
)	O
,	O
whereas	O
these	O
changes	O
were	O
not	O
found	O
in	O
high	O
mannitol	O
(	O
30	O
mmol/l	O
)	O
,	O
IL-1	B-protein
beta	I-protein
,	O
or	O
TNF	B-protein
alpha	I-protein
-stimulated	O
mesangial	O
cells	O
.	O
Cells	O
exposed	O
to	O
high-glucose	O
(	O
15	O
,	O
30	O
,	O
or	O
60	O
mmol/l	O
)	O
or	O
osmotic	O
agents	O
(	O
L-glucose	O
,	O
raffinose	O
and	O
mannitol	O
)	O
showed	O
that	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
expression	O
began	O
to	O
increase	O
after	O
24	O
h	O
,	O
reached	O
its	O
maximum	O
at	O
24	O
and	O
48	O
h	O
and	O
gradually	O
decreased	O
afterwards	O
.	O
The	O
stimulatory	O
effects	O
of	O
high	O
glucose	O
and	O
high	O
mannitol	O
on	O
mRNA	O
expression	O
were	O
observed	O
as	O
early	O
as	O
6	O
h	O
and	O
reached	O
its	O
maximum	O
at	O
12	O
h	O
.	O
Up-regulation	O
of	O
ICAM-1	B-protein
protein	O
and	O
mRNA	O
was	O
also	O
found	O
in	O
IL-1-beta	B-protein
and	O
TNF-alpha	B-protein
-stimulated	O
mesangial	O
cells	O
.	O
Neither	O
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
protein	O
nor	O
mRNA	O
expression	O
was	O
,	O
however	O
,	O
affected	O
by	O
high	O
glucose	O
and	O
high	O
mannitol	O
.	O
Notably	O
,	O
the	O
protein	O
kinase	O
C	O
inhibitors	O
calphostin	O
C	O
and	O
staurosporine	O
reduced	O
high	O
glucose-	O
or	O
high	O
mannitol-induced	O
intercellular	O
adhesion	O
molecule-1	O
mRNA	O
expression	O
and	O
high	O
glucose-induced	O
proliferation	O
.	O
Furthermore	O
,	O
the	O
NF-kappa	O
B	O
inhibitor	O
N-tosyl-L-phenylalanine	O
chloromethyl	O
ketone	O
reduced	O
high	O
glucose-	O
or	O
high	O
mannitol-induced	O
intercellular	O
adhesion	O
molecule-1	O
mRNA	O
expression	O
and	O
high	O
glucose-induced	O
proliferation	O
.	O
Results	O
showed	O
that	O
high	O
glucose	O
(	O
15	O
,	O
30	O
mmol/l	O
)	O
or	O
high	O
concentrations	O
of	O
osmotic	O
agents	O
remarkably	O
increased	O
the	O
number	O
of	O
adherent	O
leukocytes	O
to	O
mesangial	O
cells	O
(	O
p	O
<	O
0.01	O
)	O
compared	O
with	O
control	O
cells	O
(	O
5	O
mmol/l	O
D-glucose	O
)	O
.	O
Functional	O
blocking	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
on	O
mesangial	O
cells	O
with	O
rat	B-protein
intercellular	I-protein
adhesion	I-protein
molecule-1	I-protein
monoclonal	I-protein
antibody	I-protein
,	O
calphostin	O
C	O
,	O
staurosporine	O
,	O
or	O
N-tosyl-L-phenylalanine	O
chloromethyl	O
ketone	O
significantly	O
inhibited	O
high	O
glucose-	O
or	O
high	O
mannitol-induced	O
increase	O
in	O
leukocyte	O
adhesion	O
(	O
p	O
<	O
<	O
0.05	O
)	O
.	O
CONCLUSION/INTERPRETATION	O
:	O
These	O
results	O
suggest	O
that	O
high	O
glucose	O
can	O
upregulate	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
protein	O
and	O
mRNA	O
expression	O
but	O
not	O
vascular	O
adhesion	O
molecule-1	O
expression	O
in	O
mesangial	O
cells	O
and	O
promote	O
leukocyte	O
adhesion	O
through	O
up-regulation	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
through	O
osmotic	O
effect	O
,	O
possibly	O
depending	O
on	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
PKC	B-protein
-	O
NF-kappa	B-protein
B	I-protein
)	O
pathway	O
.	O
High	O
glucose	O
itself	O
can	O
also	O
promote	O
mesangial	O
cell	O
proliferation	O
through	O
the	O
PKC-NF-kappa	O
B	O
pathways	O
.	O
We	O
conclude	O
that	O
hyperglycaemia	O
in	O
itself	O
seems	O
to	O
be	O
an	O
important	O
factor	O
in	O
the	O
development	O
of	O
early	O
diabetic	O
nephropathy	O
.	O
Combined	O
corticosteroid/	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
therapy	O
in	O
the	O
treatment	O
of	O
severe	O
congenital	O
neutropenia	O
unresponsive	O
to	O
G-CSF	B-protein
:	O
Activated	O
glucocorticoid	B-protein
receptors	I-protein
synergize	O
with	O
G-CSF	B-protein
signals	O
.	O
More	O
than	O
90	O
%	O
of	O
patients	O
with	O
severe	O
congenital	O
neutropenia	O
(	O
SCN	O
)	O
respond	O
to	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
therapy	O
.	O
The	O
basis	O
for	O
the	O
refractory	O
state	O
in	O
the	O
remaining	O
patients	O
is	O
unknown	O
.	O
To	O
address	O
this	O
issue	O
,	O
we	O
studied	O
a	O
child	O
with	O
SCN	O
who	O
was	O
totally	O
unresponsive	O
to	O
G-CSF	B-protein
and	O
had	O
a	O
novel	O
point	O
mutation	O
in	O
the	O
extracellular	B-protein
domain	I-protein
of	O
the	O
G-CSF	B-protein
receptor	I-protein
(	O
GCSF-R	B-protein
)	O
.	O
Marrow	O
stromal	O
support	O
of	O
granulopoiesis	O
was	O
evaluated	O
by	O
plating	O
CD34	O
(	O
+	O
)	O
cells	O
on	O
preformed	O
stromal	O
layers	O
.	O
Nonadherent	O
cells	O
were	O
harvested	O
and	O
assayed	O
in	O
clonogenic	O
assays	O
for	O
granulocytic	O
colony	O
production	O
.	O
The	O
in	O
vitro	O
effect	O
of	O
G-CSF	B-protein
and	O
corticosteroids	O
on	O
granulopoiesis	O
was	O
evaluated	O
in	O
clonogenic	O
assays	O
of	O
marrow	O
mononuclear	O
cells	O
,	O
by	O
proliferation	O
studies	O
of	O
the	O
murine	O
myeloid	O
cell	O
line	O
32D	O
expressing	O
the	O
patient	O
's	O
mutated	B-protein
G-CSFR	I-protein
,	O
and	O
by	O
measuring	O
STAT5	O
activation	O
in	O
nuclear	O
extracts	O
from	O
stimulated	O
cells	O
.	O
Patient	O
's	O
stroma	O
supported	O
granulopoiesis	O
derived	O
from	O
control	O
marrow	O
CD34	O
(	O
+	O
)	O
cells	O
in	O
a	O
normal	O
manner	O
.	O
Normal	O
stroma	O
,	O
however	O
,	O
failed	O
to	O
induce	O
granulopoiesis	O
from	O
patient	O
's	O
CD34	O
(	O
+	O
)	O
cells	O
.	O
Clonogenic	O
assays	O
of	O
the	O
patient	O
's	O
marrow	O
mononuclear	O
cells	O
incorporating	O
either	O
G-CSF	B-protein
or	O
hydrocortisone	O
produced	O
little	O
neutrophil	O
growth	O
.	O
In	O
contrast	O
,	O
inclusion	O
of	O
both	O
G-CSF	B-protein
and	O
hydrocortisone	O
in	O
the	O
cytokine	B-protein
``	I-protein
cocktail	I-protein
''	I-protein
markedly	O
increased	O
the	O
neutrophil	O
numbers	O
.	O
Proliferation	O
of	O
32D	O
cells	O
expressing	O
the	O
mutated	B-protein
receptor	I-protein
and	O
STAT5	O
activation	O
were	O
improved	O
by	O
a	O
combination	O
of	O
G-CSF	B-protein
and	O
dexamethasone	O
.	O
When	O
small	O
daily	O
doses	O
of	O
oral	O
prednisone	O
were	O
then	O
administered	O
to	O
the	O
patient	O
with	O
conventional	O
doses	O
of	O
subcutaneous	B-protein
G-CSF	I-protein
,	O
the	O
patient	O
responded	O
with	O
increased	O
neutrophil	O
numbers	O
and	O
with	O
a	O
complete	O
reversal	O
of	O
the	O
infectious	O
problems	O
.	O
These	O
data	O
provide	O
insight	O
into	O
SCN	O
unresponsive	O
to	O
standard	O
G-CSF	B-protein
treatment	O
and	O
to	O
the	O
potential	O
corrective	O
action	O
of	O
combined	O
treatment	O
with	O
G-CSF	B-protein
and	O
corticosteroids	O
through	O
synergistic	O
activation	O
of	O
STAT5	B-protein
.	O
Human	O
renal	O
mesangial	O
cells	O
are	O
a	O
target	O
for	O
the	O
anti-inflammatory	O
action	O
of	O
9-cis	O
retinoic	O
acid	O
.	O
Mesangial	O
cells	O
play	O
an	O
active	O
role	O
in	O
the	O
inflammatory	O
response	O
to	O
glomerular	O
injury	O
.	O
We	O
have	O
studied	O
in	O
cultured	O
human	O
mesangial	O
cells	O
(	O
CHMC	O
)	O
several	O
effects	O
of	O
9-cis	O
retinoic	O
acid	O
(	O
9-cRA	O
)	O
,	O
an	O
activator	O
of	O
both	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
and	O
retinoid	B-protein
X	I-protein
receptors	I-protein
(	O
RXRs	B-protein
)	O
.	O
9-cRA	O
inhibited	O
foetal	O
calf	O
serum-induced	O
CHMC	O
proliferation	O
.	O
It	O
also	O
prevented	O
CHMC	O
death	O
induced	O
by	O
the	O
inflammatory	O
mediator	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
.	O
This	O
preventive	O
effect	O
was	O
not	O
due	O
to	O
any	O
increase	O
in	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
catabolism	O
and	O
it	O
persisted	O
even	O
when	O
both	O
catalase	O
and	O
glutathione	O
synthesis	O
were	O
inhibited	O
.	O
Finally	O
,	O
9-cRA	O
diminished	O
monocyte	O
adhesion	O
to	O
FCS-stimulated	O
CHMC	O
.	O
Interestingly	O
,	O
the	O
retinoid	O
also	O
inhibited	O
in	O
FCS-stimulated	O
cells	O
the	O
protein	O
expression	O
of	O
two	O
mesangial	B-protein
adhesion	I-protein
molecules	I-protein
,	O
fibronectin	B-protein
and	O
osteopontin	B-protein
,	O
but	O
it	O
did	O
not	O
modify	O
the	O
protein	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O
All	O
major	O
RARs	B-protein
and	I-protein
RXRs	I-protein
isotypes	I-protein
were	O
expressed	O
in	O
CHMC	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
9-cRA	O
.	O
Transcripts	O
to	O
RAR-alpha	O
,	O
RAR-beta	O
and	O
RXR-alpha	O
increased	O
after	O
incubation	O
with	O
9-cRA	O
whereas	O
RXR-gamma	O
was	O
inhibited	O
,	O
suggesting	O
a	O
major	O
role	O
for	O
RARs	B-protein
and	O
RXRs	B-protein
in	O
9-cRA-anti-inflammatory	O
effects	O
.	O
9-cRA	O
was	O
toxic	O
only	O
at	O
50	O
microM	O
(	O
a	O
concentration	O
50	O
-	O
5000	O
times	O
higher	O
than	O
required	O
for	O
the	O
effects	O
above	O
)	O
.	O
Cell	O
death	O
occurred	O
by	O
apoptosis	O
,	O
whose	O
onset	O
was	O
associated	O
with	O
a	O
pronounced	O
increase	O
in	O
catalase	O
activity	O
and	O
reduced	O
glutathione	O
content	O
,	O
being	O
more	O
effectively	O
induced	O
by	O
all-trans	O
retinoic	O
acid	O
.	O
Modulation	O
of	O
the	O
oxidant/antioxidant	O
balance	O
failed	O
to	O
inhibit	O
apoptosis	O
.	O
We	O
conclude	O
that	O
mesangial	O
cells	O
might	O
be	O
a	O
target	O
for	O
the	O
treatment	O
of	O
inflammatory	O
glomerulopathies	O
with	O
9-cRA	O
.	O
Expression	O
of	O
mammalian	O
defensin	O
genes	O
.	O
Antimicrobial	O
peptides	O
are	O
a	O
prevalent	O
mechanism	O
of	O
host	O
defense	O
found	O
throughout	O
nature	O
.	O
In	O
mammals	O
,	O
defensins	B-protein
are	O
among	O
the	O
most	O
abundant	O
of	O
these	O
broad-spectrum	O
antibiotics	O
,	O
and	O
are	O
expressed	O
in	O
epithelial	O
and	O
hematopoietic	O
cells	O
.	O
The	O
defensin	O
peptides	O
are	O
especially	O
abundant	O
in	O
neutrophils	O
;	O
however	O
,	O
gene	O
expression	O
is	O
limited	O
to	O
the	O
promyelocyte	O
stage	O
.	O
In	O
epithelial	O
cells	O
,	O
defensin	O
genes	O
are	O
found	O
as	O
both	O
constitutively	O
expressed	O
and	O
inducible	O
.	O
Induction	O
has	O
been	O
observed	O
in	O
vitro	O
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
as	O
well	O
as	O
inflammatory	O
mediators	O
.	O
In	O
vivo	O
,	O
up-regulation	O
of	O
several	O
defensin	O
genes	O
occurs	O
in	O
both	O
infectious	O
and	O
inflammatory	O
states	O
.	O
Gene	O
regulation	O
occurs	O
via	O
signal	O
transduction	O
pathways	O
common	O
to	O
other	O
innate	O
immune	O
responses	O
,	O
utilizing	O
transcription	B-protein
factors	I-protein
such	O
as	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	I-protein
and	O
NF	B-protein
interleukin-6	I-protein
.	O
Together	O
,	O
the	O
data	O
suggest	O
a	O
broad-based	O
innate	O
host	O
defense	O
whereby	O
potent	O
antimicrobial	O
peptides	O
are	O
present	O
to	O
prevent	O
initial	O
colonization	O
by	O
pathogenic	O
microorganisms	O
.	O
In	O
addition	O
,	O
the	O
recognition	O
of	O
bacteria	O
coupled	O
with	O
a	O
nascent	O
inflammatory	O
response	O
can	O
bolster	O
this	O
defense	O
by	O
a	O
coordinated	O
up-regulation	O
of	O
the	O
peptides	O
.	O
Multiple	O
signals	O
required	O
for	O
cyclic	B-protein
AMP-responsive	I-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
binding	O
protein	O
interaction	O
induced	O
by	O
CD3/CD28	O
costimulation	O
.	O
The	O
optimal	O
activation	O
of	O
cAMP-responsive	B-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
,	O
similar	O
to	O
the	O
full	O
activation	O
of	O
T	O
lymphocytes	O
,	O
requires	O
the	O
stimulation	O
of	O
both	O
CD3	B-protein
and	O
CD28	B-protein
.	O
Using	O
a	O
reporter	O
system	O
to	O
detect	O
interaction	O
of	O
CREB	B-protein
and	O
CREB-binding	B-protein
protein	I-protein
(	O
CBP	B-protein
)	O
,	O
in	O
this	O
study	O
we	O
found	O
that	O
CREB	B-protein
binds	O
to	O
CBP	B-protein
only	O
by	O
engagement	O
of	O
both	O
CD3	B-protein
and	O
CD28	B-protein
.	O
CD3/CD28	B-protein
-promoted	O
CREB	B-protein
-	O
CBP	B-protein
interaction	O
was	O
dependent	O
on	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
and	O
calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
(	I-protein
CaMK	I-protein
)	I-protein
IV	I-protein
in	O
addition	O
to	O
the	O
previously	O
identified	O
extracellular	O
signal-regulated	O
kinase	O
pathway	O
.	O
Extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
,	I-protein
CaMKIV	I-protein
,	O
and	O
p38	B-protein
MAPK	I-protein
were	O
also	O
the	O
kinases	O
involved	O
in	O
CREB	B-protein
Ser	O
(	O
133	O
)	O
phosphorylation	O
induced	O
by	O
CD3/CD28	B-protein
.	O
A	O
reconstitution	O
experiment	O
illustrated	O
that	O
optimum	O
CREB	B-protein
-	O
CBP	B-protein
interaction	O
and	O
CREB	B-protein
trans-activation	O
were	O
attained	O
when	O
these	O
three	O
kinase	O
pathways	O
were	O
simultaneously	O
activated	O
in	O
T	O
cells	O
.	O
Our	O
results	O
demonstrate	O
that	O
coordinated	O
activation	O
of	O
different	O
kinases	B-protein
leads	O
to	O
full	O
activation	O
of	O
CREB	B-protein
.	O
Notably	O
,	O
CD28	O
ligation	O
activated	O
p38	B-protein
MAPK	I-protein
and	O
CaMKIV	B-protein
,	O
the	O
kinases	B-protein
stimulated	O
by	O
CD3	O
engagement	O
,	O
suggesting	O
that	O
CD28	B-protein
acts	O
by	O
increasing	O
the	O
activation	O
extent	O
of	O
p38	B-protein
MAPK	I-protein
and	O
CaMKIV	B-protein
.	O
These	O
results	O
support	O
the	O
model	O
of	O
a	O
minimum	O
activation	O
threshold	O
for	O
CREB	B-protein
-	O
CBP	B-protein
interaction	O
that	O
can	O
be	O
reached	O
only	O
when	O
both	O
CD3	B-protein
and	O
CD28	B-protein
are	O
stimulated	O
.	O
The	O
murine	O
IL-2	O
promoter	O
contains	O
distal	O
regulatory	O
elements	O
responsive	O
to	O
the	O
Ah	B-protein
receptor	I-protein
,	O
a	O
member	O
of	O
the	O
evolutionarily	O
conserved	O
bHLH-PAS	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
.	O
Signaling	O
through	O
the	O
TCR	B-protein
and	O
costimulatory	O
signals	O
primarily	O
control	O
transcription	O
of	O
the	O
IL-2	O
gene	O
in	O
naive	O
T	O
cells	O
.	O
The	O
minimal	O
promoter	O
necessary	O
for	O
this	O
expression	O
lies	O
proximal	O
,	O
between	O
-300	O
and	O
the	O
transcription	O
start	O
site	O
.	O
We	O
had	O
previously	O
shown	O
that	O
activation	O
of	O
the	O
arylhydrocarbon	B-protein
receptor	I-protein
(	O
AHR	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
bHLH-PAS	B-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
,	O
leads	O
to	O
increased	O
mRNA	O
expression	O
of	O
IL-2	O
in	O
murine	O
fetal	O
thymocytes	O
.	O
The	O
AHR	B-protein
is	O
abundant	O
in	O
the	O
thymus	O
and	O
may	O
play	O
a	O
role	O
for	O
the	O
development	O
of	O
the	O
immune	O
system	O
.	O
Moreover	O
,	O
its	O
overactivation	O
by	O
chemicals	O
such	O
as	O
dioxins	O
leads	O
to	O
immunosuppression	O
and	O
thymic	O
involution	O
.	O
Binding	O
motifs	O
for	O
the	O
liganded	B-protein
AHR	I-protein
can	O
be	O
identified	O
in	O
the	O
distal	O
region	O
-1300	O
to	O
-800	O
of	O
the	O
mouse	O
IL-2	O
promoter	O
.	O
We	O
show	O
here	O
that	O
these	O
DNA	O
motifs	O
,	O
the	O
so-called	O
dioxin	O
response	O
elements	O
,	O
after	O
binding	O
to	O
the	O
liganded	B-protein
AHR	I-protein
are	O
sufficient	O
to	O
transactivate	O
luciferase	O
expression	O
in	O
a	O
reporter	O
gene	O
system	O
.	O
The	O
IL-2	O
gene	O
can	O
be	O
induced	O
by	O
the	O
AHR	B-protein
also	O
in	O
thymocytes	O
in	O
vivo	O
after	O
injection	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
,	O
a	O
potent	O
ligand	O
of	O
the	O
AHR	B-protein
.	O
The	O
AHR	B-protein
mediates	O
the	O
IL-2	O
induction	O
as	O
shown	O
with	O
AHR	B-protein
-deficient	O
mice	O
.	O
However	O
,	O
in	O
spleen	O
cells	O
in	O
vitro	O
costimulation	O
via	O
the	O
TCR	B-protein
is	O
necessary	O
for	O
optimal	O
IL-2	O
gene	O
induction	O
.	O
Thus	O
,	O
the	O
IL-2	O
promoter	O
region	O
contains	O
novel	O
distal	O
regulatory	O
elements	O
that	O
can	O
be	O
addressed	O
by	O
the	O
AHR	B-protein
to	O
induce	O
IL-2	O
and	O
can	O
cooperate	O
with	O
the	O
proximal	O
promoter	O
Visualization	O
of	O
Syk-antigen	B-protein
receptor	I-protein
interactions	O
using	O
green	B-protein
fluorescent	I-protein
protein	I-protein
:	O
differential	O
roles	O
for	O
Syk	B-protein
and	O
Lyn	B-protein
in	O
the	O
regulation	O
of	O
receptor	O
capping	O
and	O
internalization	O
.	O
The	O
cross-linking	O
of	O
the	O
B	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
(	O
BCR	B-protein
)	O
is	O
coupled	O
to	O
the	O
stimulation	O
of	O
multiple	O
intracellular	O
signal	O
transduction	O
cascades	O
via	O
receptor-associated	O
,	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
of	O
both	O
the	O
Src	B-protein
and	I-protein
Syk	I-protein
families	I-protein
.	O
To	O
monitor	O
changes	O
in	O
the	O
subcellular	O
distribution	O
of	O
Syk	B-protein
in	O
B	O
cells	O
responding	O
to	O
BCR	B-protein
cross-linking	O
,	O
we	O
expressed	O
in	O
Syk	B-protein
-deficient	O
DT40	O
B	O
cells	O
a	O
fusion	B-protein
protein	I-protein
consisting	O
of	O
Syk	B-protein
coupled	O
to	O
green	B-protein
fluorescent	I-protein
protein	I-protein
.	O
Treatment	O
of	O
these	O
cells	O
with	O
anti-IgM	B-protein
Abs	I-protein
leads	O
to	O
the	O
recruitment	O
of	O
the	O
kinase	B-protein
from	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
to	O
the	O
site	O
of	O
the	O
cross-linked	B-protein
receptor	I-protein
at	O
the	O
plasma	O
membrane	O
.	O
The	O
Syk-receptor	B-protein
complexes	I-protein
aggregate	O
into	O
membrane	O
patches	O
that	O
redistribute	O
to	O
form	O
a	O
cap	O
at	O
one	O
pole	O
of	O
the	O
cell	O
.	O
Syk	B-protein
is	O
not	O
demonstrably	O
associated	O
with	O
the	O
internalized	B-protein
receptor	I-protein
.	O
Catalytically	O
active	O
Syk	B-protein
promotes	O
and	O
stabilizes	O
the	O
formation	O
of	O
tightly	B-protein
capped	I-protein
BCR	I-protein
complexes	I-protein
at	O
the	O
plasma	O
membrane	O
.	O
Lyn	B-protein
is	O
not	O
required	O
for	O
the	O
recruitment	O
of	O
Syk	B-protein
to	O
the	O
cross-linked	B-protein
receptor	I-protein
,	O
but	O
is	O
required	O
for	O
the	O
internalization	O
of	O
the	O
clustered	O
BCR	B-protein
complexes	I-protein
.	O
In	O
the	O
absence	O
of	O
Lyn	B-protein
,	O
receptor-Syk	B-protein
complexes	I-protein
at	O
the	O
plasma	O
membrane	O
are	O
long	O
lived	O
,	O
and	O
the	O
receptor-mediated	O
activation	O
of	O
the	O
NF-AT	B-protein
transcription	I-protein
factor	I-protein
is	O
enhanced	O
.	O
Thus	O
,	O
Lyn	B-protein
appears	O
to	O
function	O
to	O
negatively	O
regulate	O
aspects	O
of	O
BCR	B-protein
-dependent	O
signaling	O
by	O
stimulating	O
receptor	O
internalization	O
and	O
down-regulation	O
.	O
Renal	O
interstitial	O
fibrosis	O
is	O
reduced	O
in	O
angiotensin	B-protein
II	I-protein
type	I-protein
1a	I-protein
receptor	I-protein
-deficient	O
mice	O
.	O
Unilateral	O
ureteral	O
obstruction	O
(	O
UUO	O
)	O
results	O
in	O
tubulointerstitial	O
fibrosis	O
of	O
the	O
affected	O
kidney	O
by	O
stimulating	O
the	O
renin-angiotensin	O
system	O
.	O
This	O
study	O
established	O
a	O
UUO	O
model	O
in	O
angiotensin	B-protein
type	I-protein
1a	I-protein
receptor	I-protein
(	O
AT1a	B-protein
)	O
deficient	O
(	O
mutant	O
)	O
mice	O
to	O
elucidate	O
the	O
role	O
of	O
angiotensin	B-protein
II	I-protein
through	O
AT1a	B-protein
on	O
the	O
fibrosis	O
of	O
the	O
obstructed	O
kidney	O
(	O
OBK	O
)	O
.	O
The	O
relative	O
volume	O
of	O
the	O
tubulointerstitium	O
was	O
measured	O
by	O
an	O
image	O
analyzer	O
;	O
deposition	O
of	O
collagen	B-protein
types	I-protein
III	I-protein
and	I-protein
IV	I-protein
and	O
monocyte	O
/	O
macrophage	O
infiltration	O
were	O
histologically	O
examined	O
using	O
specific	B-protein
antibodies	I-protein
.	O
Also	O
determined	O
were	O
the	O
mRNA	O
levels	O
of	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
by	O
Northern	O
blot	O
analysis	O
.	O
Nuclear	B-protein
factor-kappaB	I-protein
activity	O
was	O
assessed	O
by	O
gel	O
shift	O
assay	O
.	O
UUO	O
in	O
wild	O
mice	O
resulted	O
in	O
a	O
marked	O
expansion	O
of	O
relative	O
volume	O
of	O
the	O
tubulointerstitium	O
,	O
together	O
with	O
increased	O
deposition	O
of	O
collagen	B-protein
types	I-protein
III	I-protein
and	I-protein
IV	I-protein
and	O
number	O
of	O
infiltrated	O
monocytes	O
/	O
macrophages	O
in	O
the	O
interstitium	O
,	O
relative	O
to	O
sham-operated	O
mice	O
.	O
In	O
comparison	O
,	O
these	O
changes	O
were	O
significantly	O
lower	O
in	O
mutant	O
mice	O
with	O
UUO	O
.	O
The	O
mRNA	O
level	O
of	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
was	O
significantly	O
higher	O
in	O
the	O
OBK	O
of	O
wild	O
mice	O
with	O
UUO	O
compared	O
with	O
sham-operated	O
mice	O
.	O
In	O
contrast	O
,	O
the	O
increase	O
in	O
mRNA	O
level	O
in	O
the	O
OBK	O
of	O
mutant	O
mice	O
was	O
significantly	O
less	O
than	O
in	O
wild	O
mice	O
.	O
Finally	O
,	O
UUO	O
resulted	O
in	O
activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
in	O
wild	O
mice	O
but	O
was	O
inhibited	O
in	O
the	O
OBK	O
of	O
mutant	O
mice	O
.	O
The	O
results	O
provide	O
direct	O
evidence	O
that	O
angiotensin	B-protein
II	I-protein
acting	O
via	O
the	O
AT1a	B-protein
plays	O
a	O
pivotal	O
role	O
in	O
the	O
development	O
of	O
tubulointerstitial	O
fibrosis	O
in	O
UUO	O
.	O
HLA-DQ	B-protein
tetramers	I-protein
identify	O
epitope-specific	O
T	O
cells	O
in	O
peripheral	O
blood	O
of	O
herpes	O
simplex	O
virus	O
type	O
2-infected	O
individuals	O
:	O
direct	O
detection	O
of	O
immunodominant	O
antigen-responsive	O
cells	O
.	O
Ag-specific	O
CD4+	O
T	O
cells	O
are	O
present	O
in	O
peripheral	O
blood	O
in	O
low	O
frequency	O
,	O
where	O
they	O
undergo	O
recruitment	O
and	O
expansion	O
during	O
immune	O
responses	O
and	O
in	O
the	O
pathogenesis	O
of	O
numerous	O
autoimmune	O
diseases	O
.	O
MHC	B-protein
tetramers	I-protein
,	O
which	O
constitute	O
a	O
labeled	B-protein
MHC-peptide	I-protein
ligand	I-protein
suitable	O
for	O
binding	O
to	O
the	O
Ag-specific	B-protein
receptor	I-protein
on	O
T	O
cells	O
,	O
provide	O
a	O
novel	O
approach	O
for	O
the	O
detection	O
and	O
characterization	O
of	O
such	O
rare	O
cells	O
.	O
In	O
this	O
study	O
,	O
we	O
utilized	O
this	O
technology	O
to	O
identify	O
HLA	B-protein
DQ	I-protein
-restricted	O
Ag-specific	O
T	O
cells	O
in	O
the	O
peripheral	O
blood	O
of	O
human	O
subjects	O
and	O
to	O
identify	O
immunodominant	O
epitopes	O
associated	O
with	O
viral	O
infection	O
.	O
Peptides	O
representing	O
potential	O
epitope	B-protein
regions	I-protein
of	O
the	O
VP16	B-protein
protein	I-protein
from	O
HSV-2	O
were	O
loaded	O
onto	O
recombinant	B-protein
DQ0602	I-protein
molecules	I-protein
to	O
generate	O
a	O
panel	O
of	O
Ag-specific	B-protein
DQ0602	I-protein
tetramers	I-protein
.	O
VP16	B-protein
Ag	I-protein
-specific	O
DQ-restricted	O
T	O
cells	O
were	O
identified	O
and	O
expanded	O
from	O
the	O
peripheral	O
blood	O
of	O
HSV-2-infected	O
individuals	O
,	O
representing	O
two	O
predominant	O
epitope	O
specificities	O
.	O
Although	O
the	O
VP16	O
369-380	O
peptide	O
has	O
a	O
lower	O
binding	O
affinity	O
for	O
DQ0602	B-protein
molecules	I-protein
than	O
the	O
VP16	O
33-52	O
peptide	O
,	O
T	O
cells	O
that	O
recognized	O
the	O
VP16	O
369-380	O
peptide	O
occurred	O
at	O
a	O
much	O
higher	O
frequency	O
than	O
those	O
that	O
were	O
specific	O
for	O
the	O
VP16	O
33-52	O
peptide	O
.	O
Down-regulation	O
of	O
BOB.1/OBF.1	B-protein
and	O
Oct2	B-protein
in	O
classical	O
Hodgkin	O
disease	O
but	O
not	O
in	O
lymphocyte	O
predominant	O
Hodgkin	O
disease	O
correlates	O
with	O
immunoglobulin	O
transcription	O
.	O
In	O
contrast	O
to	O
the	O
tumor	O
cells	O
(	O
L	O
&	O
H	O
cells	O
)	O
of	O
lymphocyte	O
predominant	O
Hodgkin	O
disease	O
(	O
LPHD	O
)	O
,	O
Hodgkin	O
and	O
Reed-Sternberg	O
(	O
HRS	O
)	O
cells	O
of	O
classical	O
Hodgkin	O
disease	O
(	O
cHD	O
)	O
are	O
unable	O
to	O
transcribe	O
immunoglobulin	B-protein
,	O
despite	O
the	O
presence	O
of	O
rearranged	O
immunoglobulin	O
genes	O
.	O
Although	O
initial	O
studies	O
have	O
suggested	O
crippling	O
immunoglobulin	O
gene	O
mutations	O
to	O
be	O
the	O
cause	O
of	O
absent	O
immunoglobulin	O
expression	O
in	O
cHD	O
,	O
recent	O
work	O
of	O
our	O
group	O
has	O
demonstrated	O
an	O
impaired	O
activation	O
of	O
the	O
immunoglobulin	O
promoter	O
as	O
a	O
superior	O
mechanism	O
.	O
As	O
immunoglobulin	O
transcription	O
is	O
mainly	O
regulated	O
by	O
the	O
B-cell	B-protein
transcription	I-protein
factors	I-protein
Oct2	B-protein
and	O
BOB.1/OBF.1	B-protein
,	O
we	O
analyzed	O
35	O
cases	O
of	O
LPHD	O
,	O
32	O
cases	O
of	O
cHD	O
,	O
and	O
2	O
Hodgkin	O
disease	O
cell	O
lines	O
for	O
the	O
expression	O
of	O
these	O
transcription	B-protein
factors	I-protein
and	O
also	O
in	O
parallel	O
for	O
immunoglobulin	O
expression	O
.	O
Our	O
results	O
demonstrate	O
an	O
absence	O
of	O
Oct2	B-protein
and/or	O
BOB.1/OBF.1	B-protein
in	O
cHD	O
and	O
a	O
striking	O
overexpression	O
of	O
Oct2	B-protein
in	O
LPHD	O
.	O
Immunoglobulin	O
expression	O
was	O
lacking	O
in	O
cHD	O
but	O
present	O
in	O
LPHD	O
.	O
Furthermore	O
,	O
the	O
reintroduction	O
of	O
BOB.1/OBF.1	B-protein
and	O
Oct2	B-protein
into	O
cultured	O
HRS	O
cells	O
restored	O
the	O
activity	O
of	O
cotransduced	O
immunoglobulin	O
promoter	O
constructs	O
.	O
Our	O
findings	O
dismiss	O
the	O
concept	O
that	O
the	O
different	O
immunoglobulin	O
expression	O
in	O
cHD	O
and	O
LPHD	O
is	O
due	O
to	O
disrupting	O
mutations	O
of	O
immunoglobulin	O
V	O
genes	O
in	O
cHD	O
but	O
is	O
most	O
likely	O
due	O
to	O
a	O
down-regulation	O
of	O
Oct2	B-protein
and/or	O
BOB.1/OBF.1	B-protein
.	O
This	O
study	O
further	O
revealed	O
Oct2	B-protein
as	O
a	O
new	O
and	O
valuable	O
marker	O
for	O
the	O
identification	O
of	O
L	O
&	O
H	O
cells	O
and	O
their	O
distinction	O
from	O
HRS	O
cells	O
.	O
The	O
impairment	O
of	O
immunoglobulin	O
transcription	O
with	O
a	O
down-regulated	O
synthesis	O
of	O
Oct2	B-protein
and	O
BOB.1/OBF.1	B-protein
is	O
the	O
first	O
established	O
general	O
recurrent	O
defect	O
found	O
in	O
HRS	O
cells	O
.	O
Constitutive	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
a	O
characteristic	O
feature	O
of	O
mycosis	O
fungoides	O
:	O
implications	O
for	O
apoptosis	O
resistance	O
and	O
pathogenesis	O
.	O
The	O
NF-kappa	B-protein
B	I-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
is	O
an	O
important	O
regulator	O
of	O
genes	O
expressed	O
during	O
inflammatory	O
responses	O
,	O
immunoglobulin	O
(	O
Ig	O
)	O
class	O
switching	O
,	O
cellular	O
differentiation	O
,	O
and	O
apoptosis	O
.	O
Recently	O
,	O
members	O
of	O
the	O
NF-kappaB	B-protein
family	I-protein
,	O
including	O
p65	B-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
,	O
have	O
been	O
implicated	O
in	O
promoting	O
survival	O
of	O
various	O
hematopoeitic	O
neoplasms	O
,	O
including	O
T	O
cell	O
malignancies	O
such	O
as	O
adult	O
T	O
cell	O
leukemia-lymphoma	O
.	O
We	O
investigated	O
the	O
expression	O
of	O
active	B-protein
NF-kappa	I-protein
B	I-protein
p65	I-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
in	O
cases	O
of	O
mycosis	O
fungoides	O
(	O
MF	O
)	O
and	O
the	O
effect	O
of	O
chemical	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
on	O
apoptosis	O
in	O
cutaneous	O
T	O
cell	O
lymphoma	O
(	O
CTCL	O
)	O
cell	O
lines	O
.	O
Paraffin-embedded	O
tissues	O
from	O
23	O
cutaneous	O
lesions	O
and	O
a	O
single	O
lymph	O
node	O
biopsy	O
from	O
patients	O
diagnosed	O
with	O
MF	O
were	O
evaluated	O
for	O
p65	O
(	O
Rel	O
A	O
)	O
expression	O
by	O
using	O
a	O
monoclonal	B-protein
mouse	I-protein
antibody	I-protein
that	O
detects	O
the	O
activated	O
form	O
of	O
p65	B-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
.	O
Apoptosis	O
after	O
treatment	O
with	O
the	O
NF-kappa	O
B	O
inhibitors	O
gliotoxin	O
,	O
MG132	O
,	O
BAY	O
11-7082	O
,	O
and	O
BAY	O
11-7085	O
was	O
quantitatively	O
measured	O
in	O
the	O
CTCL	O
cell	O
lines	O
HuT-78	O
and	O
HH	O
by	O
propidium	O
iodide	O
(	O
PI	O
)	O
/cell	O
cycle	O
analysis	O
for	O
detection	O
of	O
a	O
hypodiploid	O
(	O
sub-G	O
(	O
0	O
)	O
)	O
population	O
and	O
by	O
determination	O
of	O
increased	O
Annexin	O
V/7-amino-actinomycin	O
D	O
(	O
7-AAD	O
)	O
expression	O
.	O
Nuclear	O
extracts	O
from	O
CTCL	O
cells	O
before	O
and	O
after	O
chemical	O
inhibition	O
were	O
analyzed	O
for	O
NF-kappa	O
B	O
nuclear	O
DNA-binding	O
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
quantitative	O
densitometry	O
.	O
Nuclear	O
expression	O
of	O
p65	B-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
before	O
and	O
after	O
treatment	O
with	O
the	O
various	O
inhibitory	O
compounds	O
was	O
measured	O
by	O
immunofluorescence	O
staining	O
in	O
each	O
CTCL	O
cell	O
line	O
.	O
Neoplastic	O
T	O
lymphocytes	O
from	O
22	O
of	O
24	O
cases	O
of	O
MF	O
showed	O
strong	O
nuclear	O
and	O
cytoplasmic	O
expression	O
of	O
active	B-protein
p65	I-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
.	O
Compared	O
with	O
untreated	O
control	O
cells	O
,	O
a	O
marked	O
increase	O
in	O
apoptosis	O
,	O
a	O
significant	O
decrease	O
in	O
NF-kappa	O
B	O
DNA-binding	O
activity	O
,	O
and	O
a	O
marked	O
decrease	O
in	O
nuclear	O
p65	O
(	O
Rel	O
A	O
)	O
expression	O
were	O
seen	O
in	O
cells	O
from	O
both	O
CTCL	O
cell	O
lines	O
after	O
chemical	O
NF-kappa	O
B	O
inhibition	O
.	O
These	O
data	O
show	O
that	O
the	O
active	O
form	O
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
is	O
commonly	O
expressed	O
in	O
neoplastic	O
T	O
lymphocytes	O
in	O
patients	O
with	O
MF	O
.	O
In	O
CTCL	O
cell	O
lines	O
,	O
the	O
significant	O
decrease	O
in	O
nuclear	O
NF-kappa	O
B	O
expression	O
and	O
the	O
marked	O
increase	O
in	O
spontaneous	O
apoptosis	O
caused	O
by	O
chemical	O
NF-kappa	O
B	O
inhibition	O
suggest	O
a	O
critical	O
role	O
for	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
pathogenesis	O
and	O
tumor	O
cell	O
maintenance	O
of	O
CTCLs	O
.	O
HUM	O
PATHOL	O
31	O
:	O
1482-1490	O
.	O
Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
tax	B-protein
protein	I-protein
activates	O
transcription	O
through	O
AP-1	O
site	O
by	O
inducing	O
DNA	O
binding	O
activity	O
in	O
T	O
cells	O
.	O
Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	B-protein
protein	I-protein
induces	O
the	O
expression	O
of	O
various	O
family	O
members	O
of	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
,	O
such	O
as	O
c-Jun	B-protein
,	O
JunD	B-protein
,	O
c-Fos	B-protein
,	O
and	O
Fra-1	B-protein
,	O
at	O
the	O
level	O
of	O
RNA	O
expression	O
in	O
T	O
cells	O
.	O
We	O
examined	O
the	O
activity	O
of	O
Tax	B-protein
in	O
transcription	O
through	O
AP-1-binding	O
sites	O
(	O
AP-1	O
site	O
)	O
in	O
T	O
cells	O
.	O
Transient	O
transfection	O
studies	O
showed	O
that	O
Tax	B-protein
activated	O
the	O
expression	O
of	O
a	O
luciferase	O
gene	O
regulated	O
by	O
two	O
copies	O
of	O
an	O
AP-1	O
site	O
in	O
the	O
human	O
Jurkat	O
T-cell	O
line	O
.	O
Tax	B-protein
activates	O
the	O
expression	O
of	O
viral	O
and	O
cellular	O
genes	O
through	O
two	O
different	O
enhancers	O
:	O
a	O
cAMP-responsive	O
(	O
CRE	O
)	O
-like	O
element	O
and	O
a	O
kappaB	O
element	O
.	O
Two	O
Tax	B-protein
mutants	I-protein
differentially	O
activated	O
expression	O
of	O
these	O
two	O
elements	O
.	O
Tax703	B-protein
preferentially	O
activated	O
the	O
kappaB	O
element	O
but	O
not	O
the	O
CRE-like	O
one	O
,	O
whereas	O
TaxM22	B-protein
showed	O
the	O
reverse	O
.	O
In	O
addition	O
,	O
Tax703	B-protein
and	O
Tax	B-protein
,	O
but	O
not	O
TaxM22	B-protein
,	O
converted	O
cell	O
growth	O
of	O
a	O
mouse	O
T-cell	O
line	O
from	O
being	O
interleukin	O
(	O
IL	O
)	O
-2-dependent	O
to	O
being	O
IL-2-independent	O
.	O
Unlike	O
the	O
wild-type	B-protein
Tax	I-protein
,	O
Tax703	B-protein
and	O
TaxM22	B-protein
only	O
weakly	O
activated	O
the	O
AP-1	O
site	O
in	O
the	O
T-cell	O
line	O
.	O
Thus	O
,	O
Tax	B-protein
seems	O
to	O
activate	O
the	O
AP-1	O
site	O
via	O
mechanisms	O
distinct	O
from	O
those	O
of	O
kappaB	O
or	O
CRE-like	O
elements	O
,	O
and	O
the	O
activation	O
of	O
the	O
AP-1	O
site	O
is	O
dispensable	O
for	O
IL-2-independent	O
growth	O
of	O
CTLL-2	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
Tax	B-protein
induced	O
strong	O
binding	O
activity	O
to	O
an	O
AP-1	O
site	O
in	O
CTLL-2	O
,	O
whereas	O
Tax703	B-protein
did	O
not	O
,	O
indicating	O
that	O
the	O
induction	O
of	O
binding	O
activity	O
to	O
the	O
AP-1	O
site	O
is	O
essential	O
for	O
the	O
transcriptional	O
activation	O
by	O
Tax	B-protein
.	O
The	O
binding	B-protein
complex	I-protein
induced	O
by	O
Tax	B-protein
in	O
CTLL-2	O
contained	O
JunD	B-protein
and	O
Fra-2	B-protein
.	O
Other	O
AP-1	B-protein
proteins	I-protein
were	O
undetectable	O
.	O
Activation	O
of	O
transcription	O
through	O
the	O
AP-1	O
site	O
in	O
Jurkat	O
cells	O
by	O
JunD	B-protein
and/or	O
Fra-2	B-protein
was	O
weak	O
.	O
c-Jun	B-protein
,	O
JunB	B-protein
,	O
and	O
c-Fos	B-protein
activation	O
was	O
greater	O
,	O
although	O
the	O
level	O
was	O
still	O
less	O
than	O
that	O
with	O
Tax	B-protein
.	O
Thus	O
,	O
the	O
induction	O
of	O
AP-1	O
mRNA	O
by	O
Tax	B-protein
may	O
not	O
be	O
sufficient	O
for	O
a	O
complete	O
activation	O
of	O
AP-1	O
site	O
by	O
Tax	B-protein
.	O
Our	O
results	O
suggest	O
that	O
Tax	B-protein
activates	O
the	O
transcription	O
of	O
cellular	O
genes	O
with	O
AP-1	O
sites	O
by	O
inducing	O
the	O
DNA-binding	O
activity	O
of	O
AP-1	B-protein
proteins	I-protein
in	O
T	O
cells	O
,	O
a	O
mechanism	O
distinct	O
from	O
those	O
of	O
CRE-like	O
and	O
kappaB	O
elements	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
Strict	O
control	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
genetic	O
switch	O
:	O
Tet	O
for	O
Tat	O
.	O
Live-attenuated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
variants	O
have	O
shown	O
great	O
promise	O
as	O
AIDS	O
vaccines	O
,	O
but	O
continued	O
replication	O
can	O
lead	O
to	O
the	O
selection	O
of	O
faster-replicating	O
variants	O
that	O
are	O
pathogenic	O
.	O
We	O
therefore	O
designed	O
HIV-1	O
genomes	O
that	O
replicate	O
exclusively	O
upon	O
addition	O
of	O
the	O
nontoxic	O
effector	O
doxycycline	O
(	O
dox	O
)	O
.	O
This	O
was	O
achieved	O
by	O
replacement	O
of	O
the	O
viral	O
TAR-Tat	O
system	O
for	O
transcriptional	O
activation	O
by	O
the	O
Escherichia	O
coli-derived	O
Tet	O
system	O
for	O
inducible	O
gene	O
expression	O
.	O
These	O
designer	O
``	O
HIV-rtTA	O
''	O
viruses	O
replicate	O
in	O
a	O
strictly	O
dox-dependent	O
manner	O
both	O
in	O
a	O
T-cell	O
line	O
and	O
in	O
primary	O
blood	O
cells	O
,	O
and	O
the	O
rate	O
of	O
replication	O
can	O
be	O
fine-tuned	O
by	O
simple	O
variation	O
of	O
the	O
dox	O
concentration	O
.	O
These	O
HIV-rtTA	O
viruses	O
provide	O
a	O
tool	O
to	O
perform	O
genetics	O
,	O
,	O
selection	O
and	O
optimization	O
experiments	O
,	O
with	O
the	O
E.	O
coli-derived	O
Tet	O
reagents	O
in	O
a	O
eukaryotic	O
background	O
.	O
Furthermore	O
,	O
such	O
viruses	O
may	O
represent	O
improved	O
vaccine	O
candidates	O
because	O
their	O
replication	O
can	O
be	O
turned	O
on	O
and	O
off	O
at	O
will	O
.	O
Synovial	O
fluid	O
induced	O
nuclear	B-protein
factor-kappaB	I-protein
DNA	O
binding	O
in	O
a	O
monocytic	O
cell	O
line	O
.	O
OBJECTIVE	O
:	O
To	O
determine	O
the	O
effects	O
of	O
synovial	O
fluids	O
(	O
SF	O
)	O
on	O
DNA	O
binding	O
activity	O
of	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
in	O
the	O
Mono	O
Mac	O
6	O
monocytic/macrophage	O
cell	O
line	O
as	O
a	O
model	O
for	O
the	O
interaction	O
between	O
SF	O
and	O
synovial	O
tissue	O
macrophages	O
in	O
arthritis	O
.	O
METHODS	O
:	O
Mono	O
Mac	O
6	O
cells	O
were	O
incubated	O
with	O
SF	O
from	O
the	O
knee	O
joints	O
of	O
human	O
subjects	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
undifferentiated	O
seronegative	O
oligoarthritis	O
,	O
and	O
osteoarthritis	O
(	O
OA	O
)	O
.	O
Nuclear	O
extracts	O
prepared	O
from	O
the	O
Mono	O
Mac	O
6	O
cells	O
and	O
RA	O
synovial	O
tissue	O
were	O
analyzed	O
by	O
electrophoretic	O
mobility	O
shift	O
analysis	O
(	O
EMSA	O
)	O
for	O
NF-kappaB	B-protein
DNA	I-protein
binding	I-protein
proteins	I-protein
.	O
RESULTS	O
:	O
Induction	O
of	O
NF-kappaB	B-protein
DNA	O
binding	O
by	O
the	O
p65	B-protein
(	I-protein
RelA	I-protein
)	I-protein
/p50	I-protein
heterodimer	I-protein
was	O
observed	O
in	O
response	O
to	O
incubation	O
of	O
Mono	O
Mac	O
6	O
cells	O
with	O
SF	O
(	O
20	O
%	O
in	O
culture	O
medium	O
)	O
from	O
5	O
of	O
8	O
subjects	O
with	O
RA	O
,	O
4	O
of	O
5	O
with	O
OA	O
,	O
and	O
none	O
of	O
3	O
with	O
undifferentiated	O
seronegative	O
oligoarthritis	O
.	O
Incubation	O
of	O
SF	O
with	O
neutralizing	B-protein
antibodies	I-protein
against	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	I-protein
TNF-alpha	I-protein
)	I-protein
,	O
but	O
not	O
antibodies	B-protein
against	O
interleukin	B-protein
6	I-protein
(	I-protein
IL-6	I-protein
)	I-protein
,	O
significantly	O
reduced	O
the	O
induction	O
of	O
p65/p50	O
binding	O
activity	O
in	O
SF	O
from	O
subjects	O
with	O
RA	O
and	O
OA	O
.	O
Unexpectedly	O
,	O
a	O
slowly	O
migrating	O
SF	O
inducible	O
NF-kappaB	B-protein
-binding	O
complex	O
was	O
observed	O
in	O
EMSA	O
of	O
Mono	O
Mac	O
6	O
cells	O
after	O
incubation	O
with	O
SF	O
from	O
5	O
of	O
8	O
RA	O
and	O
2	O
of	O
5	O
OA	O
subjects	O
.	O
The	O
induction	O
of	O
this	O
complex	O
by	O
SF	O
was	O
not	O
affected	O
by	O
neutralization	O
of	O
TNF-alpha	B-protein
or	O
IL-6	B-protein
in	O
SF	O
,	O
and	O
the	O
complex	O
was	O
not	O
inducible	O
by	O
TNF-alpha	B-protein
,	O
IL-1beta	O
,	O
TNF-alpha	B-protein
/	O
IL-1beta	B-protein
,	O
IL-6	B-protein
,	O
platelet	B-protein
derived	I-protein
growth	I-protein
factor	I-protein
,	O
lipopolysaccharide	O
,	O
or	O
tetradecanoyl	O
phorbol	O
acetate	O
.	O
The	O
slowly	O
migrating	B-protein
complex	I-protein
could	O
not	O
be	O
supershifted	O
with	O
antibodies	B-protein
against	O
NF-kappaB	B-protein
,	O
Jun	B-protein
,	O
or	O
the	O
transcriptional	O
coactivators	O
p300	B-protein
or	O
CBP	B-protein
.	O
A	O
NF-kappaB-binding	B-protein
complex	I-protein
with	O
similar	O
slow	O
mobility	O
was	O
observed	O
in	O
nuclear	O
extracts	O
prepared	O
from	O
fresh	O
human	O
RA	O
synovial	O
tissue	O
.	O
CONCLUSION	O
:	O
Biological	O
activity	O
of	O
TNF-alpha	B-protein
in	O
SF	O
from	O
RA	O
and	O
OA	O
subjects	O
is	O
capable	O
of	O
inducing	O
p65/p50	B-protein
NF-kappaB	I-protein
DNA	O
binding	O
activity	O
in	O
macrophages	O
.	O
A	O
property	O
of	O
SF	O
that	O
is	O
independent	O
of	O
TNF-alpha	B-protein
and	O
other	O
cytokines	B-protein
is	O
responsible	O
for	O
the	O
induction	O
of	O
a	O
novel	O
slowly	O
migrating	O
NF-kappaB-binding	B-protein
complex	I-protein
.	O
Soluble	O
mediators	O
in	O
SF	O
of	O
subjects	O
with	O
RA	O
and	O
OA	O
can	O
therefore	O
modulate	O
binding	O
of	O
nuclear	B-protein
proteins	I-protein
to	O
the	O
NF-kappaB	B-protein
binding	I-protein
site	I-protein
in	O
macrophages	O
and	O
may	O
play	O
a	O
role	O
in	O
inflammatory	O
gene	O
expression	O
in	O
arthritis	O
.	O
Peroxisome	B-protein
proliferator	I-protein
activator	I-protein
receptor-gamma	I-protein
agonists	O
and	O
15-deoxy-Delta	O
(	O
12	O
,	O
14	O
)	O
(	O
12	O
,	O
14	O
)	O
-PGJ	O
(	O
2	O
)	O
induce	O
apoptosis	O
in	O
normal	O
and	O
malignant	O
B-lineage	O
cells	O
.	O
The	O
research	O
described	O
herein	O
evaluates	O
the	O
expression	O
and	O
functional	O
significance	O
of	O
peroxisome	B-protein
proliferator	I-protein
activator	I-protein
receptor-gamma	I-protein
(	I-protein
PPAR-gamma	I-protein
)	I-protein
on	O
B-lineage	O
cells	O
.	O
Normal	O
mouse	O
B	O
cells	O
and	O
a	O
variety	O
of	O
B	O
lymphoma	O
cells	O
reflective	O
of	O
stages	O
of	O
B	O
cell	O
differentiation	O
(	O
,	O
70Z/3	O
,	O
CH31	O
,	O
WEHI-231	O
